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ABBREVIATIONS AND ACRONYMS 
 
AAV   ANCA-Associated Vasculitis (Vasculitides) 
ACR   American College of Rheumatology 
ANA    Anti-Nuclear Antibodies 
ANCA   Anti-Neutrophil Cytoplasmic Autoantibodies 
APC   Allophycocyanin 
ATG   Anti-Thymocyte Globulin 
AZA   Azathioprine 
BFA   Brefeldin A 
BPI   Bactericidal/Permeability-Increasing protein 
BVAS   Birmingham Vasculitis Activity Score 
c-ANCA  cytoplasmic Anti-Neutrophil Cytoplasmic Autoantibodies 
CCR   C-C Chemokine Receptor  
CKD   Chronic Kidney Disease 
CRTH2 Chemoattractant Receptor-Homologous Molecule expressed on 
Th2 lymphocytes 
CXCR   CXC Chemokine Receptor 
CHCC   Chapel Hill Consensus Conference 
cPR3   complementary Proteinase-3 
CR   Complete Remission 
CSS   Churg Strauss Syndrome 
CTLA-4  Cytotoxic T-Lymphocyte-associated Antigen 4 
CYC   Cyclophosphamide 
DTH   Delayed-Type Hypersensitivity 
ELISA   Enzyme-Linked Immunosorbent Assay 
ENT   Ear, Nose and Throat 
EUVAS  European Vasculitis Study Group 
FACS   Fluorescence Activated Cell Sorter 
FcγR   Receptor for the Fc fragment of immunoglobulin G  
FITC   Fluorescein Isothiocyanate 
FNGN   Focal Necrotizing Glomerulonephritis 
FoxP3   Transcription factor forkhead box P3 
FSC   Forward Scatter 
GBM    Glomerular Basement Membrane 
GM-CSF  Granulocyte-Macrophage Colony-Stimulating Factor 
GTP   Guanosine-5'-triphosphate    
HACA   Human Anti-Chimeric Antibodies  
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HC   Healthy Controls 
IFN    Interferon gamma 
Ig   Immunoglobulin 
IIF   Indirect ImmunoFluorescence 
IL   InterLeukin 
IL-2R   Receptor for Interleukin-2 
IRI   Immunoregulatory Index 
iRPGN  idiopathic (isolated) Rapidly Progressive GlomeruloNephritis 
IU   International Units 
IVIg   IntraVenous Immunoglobulin 
kDa   kiloDalton 
LAMP-2  Lysozomal-Associated Membrane Protein 2 
LPS   Lipopolysaccharide 
MMF   Mycophenolate-mofetil 
MPA   Microscopic Polyangiitis (Polyarteritis) 
MPO   Myeloperoxidase 
mRNA  messenger Ribonucleic Acid 
NK   Natural Killer 
n.s.   not significant 
p-ANCA  perinuclear Anti-Neutrophil Cytoplasmic Autoantibodies 
PE   Phycoerythrin 
PerCP   Peridinin Chlorophyll Protein 
PHA   Phytohaemaglutinin 
PMA   Phorbol 12-Myristate 13-Acetate 
PR   Partial Remission 
PR3   Proteinase-3 
RAG2   Recombination Activating Gene 2 
RLV   Renal-Limited Vasculitis 
ROS   Reactive Oxygen Species 
RPMI   Roswell Park Memorial Institute medium 
RTX   Rituximab 
s (sCD30)  soluble (soluble CD30) 
SSC   Side Scatter 
TEMs   Effector Memory T cells 
TGF    Transforming Growth Factor beta 
Th   T helper (cells) 
TNF    Tumor Necrosis Factor alpha 
Treg(s)  regulatory T cell(s) 
WG   Wegener‘s Granulomatosis 
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1. INTRODUCTION 
 
 Vasculitides are a heterogeneous group of clinico-pathologic units characterised 
by inflammatory infiltration and potential destruction of blood vessel walls. This leads 
to ischemia of the tissues supplied by the involved vessel. In some patients, systemic 
signs and symptoms, such as fever, fatigue or weight loss, may be present. Vasculitis 
can occur as the primary or sole manifestation of the disease (primary vasculitis), or in 
connection with another identified underlying trigger or disease, e.g. rheumatoid 
arthritis or systemic lupus erythematosus (secondary vasculitis). Since any type, size 
and location of blood vessels may be afflicted by vasculitis there is a whole spectrum of 
different syndromes resulting from the disease process. [1]  
 The classification of vasculitides has remained controversial during the past 
years. Various attempts have been made to develop a universally accepted classification 
scheme recently [2]. However, two so far still most commonly used classification 
systems of primary systemic vasculitides include the American College of 
Rheumatology (ACR) 1990 criteria [3] and the Chapel Hill Consensus Conference 
(CHCC) definitions proposed in 1994 [4], although the latter were not originally 
intended to be used as either classification or diagnostic criteria. According to the 
CHCC, vasculitides can be divided into large vessel, medium sized vessel and small 
vessel vasculitides based on the size of the involved vessel (Table 1.1).  
  
Table 1.1: Classification of vasculitides adopted by the Chapel Hill Consensus Conference on 
the Nomenclature of Systemic Vasculitis (1994) 
Size of involved vessels Disease entity 
Large vessel vasculitis 
 
Giant cell (temporal) arteritis 
Takayasu's arteritis 
Medium sized vessel vasculitis Polyarteritis nodosa 
Kawasaki disease 
Small vessel vasculitis Wegener's granulomatosis
*
 
Churg Strauss syndrome
*
 
Microscopic polyangiitis
*
  
(Microscopic polyarteritis) 
Henoch Schönlein Purpura 
Essential cryoglobulinaemic vasculitis 
Cutaneous leucocytoclastic angiitis 
*Strongly associated with antineutrophil cytoplasmic antibodies (ANCA). 
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 Wegener‘s granulomatosis (WG), microscopic polyangiitis (MPA) and Churg 
Strauss syndrome (CSS) (for their CHCC definitions see Table 1.2) are a group of 
systemic immune-mediated diseases with a strong and highly specific association with 
Anti-Neutrophil Cytoplasmic Autoantibodies (ANCA). Together with idiopathic 
(isolated) rapidly progressive glomerulonephritis (iRPGN) they are therefore all ranked 
among ANCA-associated vasculitides (AAV).  
  
Table 1.2: Definitions of ANCA-associated vasculitides according to the Chapel Hill 
Consensus Conference 
Disease entity Disease definition
+ 
Wegener's granulomatosis Granulomatous inflammation involving the 
respiratory tract, and necrotizing vasculitis 
affecting small to medium-sized vessels (e.g. 
capillaries, venules, arterioles, and arteries). 
Necrotizing glomerulonephritis is common. 
Churg Strauss syndrome Eosinophil-rich and granulomatous 
inflammation involving the respiratory tract, 
necrotizing vasculitis affecting small to 
medium-sized vessels, and associated with 
asthma and eosinophilia 
Microscopic polyangiitis
*
 
(microscopic polyarteritis) 
Necrotizing vasculitis, with few or no immune 
deposits, affecting small vessels (i.e. 
capillaries, venules, or arterioles). Necrotizing 
arteritis involving small and medium sized 
arteries may be present. Necrotizing 
glomerulonephritis is very common. 
Pulmonary capillaritis often occurs. 
* Preferred term.  
+
 Essential components are represented by normal type; italicised type represents usual, but not essential, 
components.  
 
 ANCA are predominantly IgG autoantibodies directed against different target 
antigens located in azurophilic granules of polymorphonuclear leucocytes and the 
peroxidase-positive lysosomes of monocytes. Nowadays, ANCA testing plays an 
important role in the diagnosis of vasculitides. In WG, ANCA are usually directed 
against proteinase 3 (PR3-ANCA) and have a cytoplasmic type of immunofluorescence 
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(c-ANCA). In MPA the target antigen is mostly myeloperoxidase (MPO-ANCA) and 
the type of immunofluorescence is perinuclear (p-ANCA). Both MPO-ANCA and, less 
frequently, PR3-ANCA can also be found in patients with CSS and iRPGN (sometimes 
referred to as renal-limited vasculitis, RLV) [5]. 
The annual incidence of AAV (in Europe approximately 10-20/million [6]) is 
not as low as it was originally believed, most probably due to higher awareness of the 
disease and the possibility of routine ANCA testing. AAV typically involve kidney, 
lungs and ENT (ear, nose and throat) organs even though, in principle, any organ may 
be afflicted. Diagnostics is based on clinical picture, ANCA testing and—when 
possible—verification by a biopsy. Untreated, generalised WG and MPA follow 
a progressive course with a fatal outcome due to vital organ failure. Standard combined 
immunosuppressive treatment consisting of cyclophosphamide and corticosteroids leads 
to successful remission achievement in most patients. Side effects of the therapy are, 
however, common; and, in the long run, many of the patients relapse. 
The pathogenesis of ANCA-associated vasculitides remains to be elucidated. 
Nevertheless, it seems to be a complex process which likely involves impaired immune 
mechanisms of both innate and adaptive, and both humoral and cellular immunity. Due 
to close correlation of ANCA and AAV, researchers primarily focused on the potential 
of ANCA to induce and promote vasculitis. In recent years, there has been increasing 
evidence that ANCA might, indeed, play a direct pathogenic role in triggering AAV. 
However, as ANCA are class-switched IgG antibodies (mainly IgG1 and IgG4) [7], 
T cells are also involved in their production by B cells and plasma cells. During the last 
few years, abnormalities in T cell subpopulations in AAV have been reported repeatedly 
and cellular immunity in AAV has attracted substantial attention. In the future, better 
understanding of pathogenic mechanisms in AAV might provide clues to improve 
diagnostic possibilities and also develop novel, targeted, therapeutic modalities. 
 In this work, current insights into the pathogenesis of AAV have been 
summarized, with emphasis placed on the role of both ANCA and T cells in the process. 
The experimental part aimed to assess the cellular immunity in AAV. The expression of 
various surface markers and the intracellular cytokine production in peripheral 
lymphocytes and monocytes in patients with AAV at different stages of the disease 
were measured by flow cytometry.  
  
  
10 
2. CURRENT INSIGHTS INTO PATHOGENESIS OF 
ANCA-ASSOCIATED VASCULITIS 
2.1 Anti-Neutrophil Cytoplasmic Autoantibodies (ANCA) 
 
 Anti-Neutrophil Cytoplasmic Autoantibodies (ANCA) were first described in 
1982 and were originally believed to be associated with Ross River virus infections [8]. 
By 1985, however, ANCA had been linked to WG [9]. Within several more years, 
a relationship among ANCA, WG and MPA had been established and proteinase 3 
(PR3) and myeloperoxidase (MPO) recognised as major autoantigens [10-12]. 
Nowadays, PR3-ANCA and MPO-ANCA testing is widely used in the diagnostics of 
vasculitides and, despite some controversy, also for monitoring disease activity.  
  
2.1.1 ANCA testing 
 
Two types of ANCA assays are currently in wide use – a more sensitive indirect 
immunofluorescence (IIF) assay and a more specific enzyme-linked immunosorbent 
assay (ELISA). To maximize diagnostic utility, combination of both methods has been 
recommended, with IIF used as a screening method and IIF positivity confirmed by 
PR3- and MPO-specific ELISAs [13-17]. Thereby, the specificity for AAV can reach 
up to 88-100% and sensitivity for AAV widely ranges from 34 to 92% [14, 16, 17]. 
Negative IIF results in patients with clinical symptoms attributable to vasculitis should 
also be tested by ELISA as 5% of serum samples are positive by ELISA only [13, 15]. 
In appropriate clinical context, ANCA testing by both IIF and ELISA can help to 
exclude or, conversely, support the diagnosis of pauci-immune necrotizing/crescentic 
glomerulonephritis (with negative and positive predictive values being 99% and 95%, 
respectively) [18].  
2.1.1.1 Indirect immunofluorescence 
 When sera of the patients with AAV are incubated with ethanol fixed human 
neutrophils, two major immunofluorescent patterns are observed.  With the classical c-
ANCA pattern (Fig. 1 on the left), the granular staining is diffuse throughout the 
cytoplasm, with internuclear accentuation (c = cytoplasmic type of 
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immunofluorescence). In most cases, antibodies directed against PR3 cause this pattern, 
but MPO-ANCA can occasionally be responsible [13, 19]. 
 The perinuclear or p-ANCA pattern (Fig. 1 on the right) results from a staining 
pattern around the nucleus (with or without nuclear extension), which represents an 
artefact of ethanol fixation. With ethanol fixation of the neutrophil substrate, positively-
charged granule constituents rearrange themselves around the negatively-charged 
nuclear membrane, leading to perinuclear fluorescence [10, 19]. The antibody 
responsible for this pattern (detected by ELISA) is usually directed against MPO (and 
occasionally PR3).  
 
                     
Fig. 2.1: ANCA: c - cytoplasmic type of immunofluorescence on the left; p - perinuclear type of 
immunofluorescence on the right [photo from the Laboratory of Immunology, Institute of 
Clinical Biochemistry and Laboratory Diagnostics] 
 
 However, p-ANCA (other than MPO- or PR3-specific) can also be detected in 
diseases different from AAV, such as in inflammatory bowel diseases and also other 
autoimmune disorders. Atypical cytoplasmic ANCA, with diffuse flat cytoplasmic 
staining without accentuation between nuclear lobules, are often linked to chronic 
infections and directed against bactericidal/permeability-increasing protein (BPI). Any 
other ANCA staining is referred to as an atypical ANCA pattern and is not considered 
typical for AAV. Nevertheless, in some cases it might resemble p-ANCA pattern [19].  
A frequent difficulty in distinguishing the p-ANCA pattern of 
immunofluorescence from that caused by antinuclear antibodies (ANA) in ethanol 
fixation might be overcome by the use of both formalin- and ethanol-fixed neutrophil 
substrates, because formalin-fixed neutrophils prevent the rearrangement of charged 
cellular components around the nucleus [20]. However, the formalin-fixed substrates are 
not used in routine practice. Generally, the IIF results have to be interpreted with 
caution as they are highly dependent on the experience of the laboratory personnel. 
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2.1.1.2 Enzyme-linked immunosorbent assays 
 Specific ELISAs for antibodies against PR3 and MPO (and in some centres for 
other antigens as well) are now available, and should form an integral part of routine 
ANCA detection in AAV patients, as stated above. PR3-ANCA and MPO-ANCA are 
possibly associated with substantially higher specificities and positive predictive values 
than the immunofluorescence patterns to which they usually correspond (c- and p-
ANCA, respectively). There are, however, significant differences in sensitivity, 
specificity and predictive values among commercially available direct ELISA kits as 
there has been no agreed international standard so far [21, 22].  
It has been noted that direct ELISA results do not always correlate with IIF 
results. The reason might be that proteins are denatured during antigen purification or 
coating onto the solid phase, thereby hiding or destroying conformational epitopes on 
PR3. In order to avoid this, capture ELISA has been designed, where the plate is 
precoated with a monoclonal antibody to capture the antigen. However, the capturing 
antibodies may compete for epitopes recognized by some PR3-ANCA, causing 
occasional false-negative results. Some data suggest an advantage of capture ELISA 
over direct ELISA, the most important being a superior diagnostic performance and 
better inter-laboratory correlation in PR3-ANCA and the ability to detect immune 
complexes [23, 24]. In a recent report, a direct PR3-ELISA was superior to a capture 
PR3-ELISA as a screening test while capture ELISA was shown a potentially more 
useful method for monitoring serial PR3-ANCA concentrations [25]. 
 
2.1.2 Pathogenic role of ANCA in ANCA-associated vasculitis 
 
Vasculitic lesions caused by small-vessel vasculitides associated with the 
presence of ANCA (i.e. WG, MPA, CSS and iRPGN) display so-called ‗pauci-immune‘ 
pattern in indirect immunofluorescence techniques and are therefore collectively 
designated as pauci-immune necrotizing vasculitides. The term pauci-immune reflects 
the relative lack of immunoglobulin and complement depositions (particularly in the 
kidneys) [5] although immune complex deposits were found on electron microscopy in 
over a half of renal biopsies [26].  
Nevertheless, the strong association of ANCA with vasculitic syndromes, their 
correlation with disease activity, and ability of ANCA increase to predict relapse in 
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some–but not all–studies [27, 28] have suggested a pathogenic role for ANCA. These 
findings may, however, be the cause as well as the result of the disease. In recent years, 
evidence for the pathogenic potential of ANCA, particularly MPO-ANCA, has emerged 
from both in vitro and in vivo studies, and will be summarized below. In addition to this, 
the first reported case of a transplacental transfer of MPO-ANCA resulting in 
a pulmonary-renal syndrome in the newborn has been published lately [29]. 
 
2.1.2.1 In vitro studies 
2.1.2.1.1 ANCA and neutrophil and monocyte activation 
In AAV, ANCA are directed against antigens located in azurophilic granules of 
polymorphonuclear leucocytes and the peroxidase-positive lysosomes of monocytes. 
The antigen is either proteinase 3 (PR3), a 29-kDa cationic protein belonging to the 
trypsin family of neutral serine proteases, or myeloperoxidase (MPO), a 140-kDa 
enzyme, which catalyses the production of hypochloric acid effective in killing 
phagocytized bacteria and viruses.  
Although ANCA antigens are normally predominantly located in the cytoplasm 
of neutrophils and monocytes, preactivation (priming) of these cells, as occurs 
following exposure to low doses of pro-inflammatory cytokines such as TNFα (tumor 
necrosis factor alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF), 
interleukin (IL)-1 or IL-8, results in the release of small amounts of ANCA antigens and 
their translocation to the cell surface, where they become accessible for interaction with 
ANCA. In vivo, these proinflammatory stimuli might, for instance, be induced by 
preceding or concomitant infectious agents [30, 31]. A strong association of the 
occurrence of relapse with chronic nasal carriage of Staphylococcus aureus in patients 
with WG has been reported [32].  
The interaction of ANCA and target antigens is followed by activation of 
neutrophils. In vitro, IgG fractions from sera that contain PR3-ANCA or MPO-ANCA 
(but not IgG fractions from healthy donors) cause cytokine-primed neutrophils to 
undergo a respiratory burst and degranulation. The degranulation of neutrophils and 
release of lytic enzymes, interleukin-I  and reactive oxygen species (ROS) cause tissue 
damage [30, 33].  Recently, also IL-18 was shown to prime ANCA-stimulated 
neutrophils for increased superoxide production, without increasing the surface 
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expression of PR3 and MPO. This process was unaffected by anti-TNF  antibodies, 
suggesting a direct role of IL-18 in neutrophil priming [34].    
Not only neutrophils but also monocytes can be activated by ANCA. Affinity-
purified PR3-ANCA and MPO-ANCA are able to induce monocytes to produce oxygen 
radicals and to increase their synthesis of cytokines and chemokines such as monocyte 
chemoattractant protein-1 and IL-8 [35-37]. 
2.1.2.1.2 Neutrophil - endothelial cell interaction in AAV  
The activation of neutrophils by ANCA only occurs when they are adherent to 
a surface [38]. In vivo, this process is assumed to occur at the endothelial surface. In in 
vitro models, binding of ANCA allows activated neutrophils and monocytes to stably 
adhere to the cytokine-primed endothelial layer with enhanced expression of adhesion 
molecules [39]. A role for adhesion molecules has been supported by the 
immunohistological evidence for upregulated adhesion molecules in glomerular lesions 
in renal biopsies of AAV patients [40]. It has been demonstrated that the interaction 
between neutrophils and endothelial cells depends on 2 integrins (CD11a/CD18 and 
CD11b/CD18) and GTP-binding chemokine receptors and that the process of neutrophil 
adherence might be in vitro inhibited by anti-CD18 antibodies [41, 42]. ANCA are able 
to stimulate the process of this adherence, presumably by upregulating CD11b on 
neutrophils as shown in an in vitro study [43], or by conformational change in CD11b 
which reveals its activation epitope as suggested by others [42].  The presence of 
ANCA leads to the detachment and lysis of endothelial cells [44]. In mediating the 
endothelial cell injury in AAV, serine proteases are supposed to play a more important 
role than reactive oxygen species [45].  Persistent ANCA binding to neutrophils on the 
endothelial surface can enhance the degree of vascular injury and also the destruction of 
the underlying tissues [46].  
In addition, primed neutrophils not only damage endothelial cells, but attract 
additional neutrophils to the site of damage, thereby creating an auto-amplifying loop. 
The release of MPO, PR3, elastase and other proteases from activated neutrophils also 
directly contributes to the local inflammatory process. Released enzymes can bind to the 
surface of unprimed neutrophils, facilitating subsequent recognition by ANCA and 
amplifying ANCA-potentiated neutrophil activation. Moreover, ANCA-mediated 
secretion of pro-inflammatory cytokines further activates other components of immune 
response, with monocytes and T lymphocytes involved [31, 47, 48]. Interestingly, in 
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vitro, the factors released from stimulated neutrophils have only recently been shown to 
also activate complement via the alternative pathway, which indicates that the so far 
neglected complement might play an important role in the complex pathogenesis of 
AAV [49].  
The presence of increased numbers of circulating endothelial cells in patients 
with active vasculitis [50] supports the hypothesis that endothelial cells are the target of 
the initial injury. This results in swelling, apoptosis/necrosis and deadherence of 
endothelial cells. Lysed neutrophil granulocytes are found within affected vessels. In the 
lung, capillaries, venules and arterioles are infiltrated by polymorphonuclear leucocytes. 
Pulmonary microvascular necrotizing vasculitis (capillaritis) is the cause of pulmonary 
hemorrhage. In the kidney, rupture of the basement membrane subsequent to neutrophil 
degranulation gives rise to glomerular capillary thrombosis followed by a cascade of 
events leading to focal segmental crescentic glomerulonephritis.  
2.1.2.1.3 ANCA binding to neutrophils and signal transduction pathways 
Notable progress has been made lately in understanding the mechanisms of 
ANCA binding and, to a lesser extent, in signal transduction pathways, even though 
precise details still remain to be elucidated.  
ANCA bind via their F(ab')2-fragments to the target antigens, i.e. surface 
expressed PR3 or MPO, and, at the same time, via their Fc fragments to Fc gamma  
receptors (FcγR) on neutrophils. Binding of ANCA to neutrophils triggers signalling 
events that lead to neutrophil activation. It has been discussed whether these signalling 
events are initiated by ANCA F(ab')2 binding to MPO or PR3 [51] or proceed via 
antibody binding to FcγRIIa and FcγRIIIb receptors [52-54] or both. To date, it seems 
highly likely that both F(ab')2 and Fc engagements are needed for effective neutrophil 
activation that leads to significant functional events, such as superoxide and pro-
inflammatory cytokines production and degranulation. Beta-2 integrins might cooperate 
with the Fc gamma receptor in propagating the signal. Fc gamma receptor interactions 
are bound to play a role in neutrophil activation by ANCA, as blockade of FcγRIIa with 
monoclonal antibodies is able to prevent the process [52, 53]. Recently, it has been 
demonstrated that ligation of FcγRIIa and FcγRIIIb is necessary for ANCA-induced 
neutrophil activation. However, the signalling cascades used by ANCA are different 
from the signal pathways used by FcγR engagement only, suggesting that ANCA 
require other not yet identified membrane cofactors for neutrophil activation than FcγR 
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mechanisms alone [54]. In brief, the so far identified signalling pathways involved in 
ANCA-mediated neutrophil activation include p38 mitogen-activated protein kinase 
(MAPK), extracellular signal-regulated kinase and phosphatidylinositol-3 kinase control 
systems [54-56].  
It has been reported that the intracellular signal transduction pathways differ 
depending on in which portion of ANCA the signal is initiated. While both ANCA IgG 
and ANCA IgG F(ab')2 fragment can activate inhibitory G proteins and p21ras protein 
activator, ANCA IgG F(ab')2 fragment is insufficient to activate tyrosin kinases 
pathways, thought to generate superoxide production [31, 57, 58]. However, both 
tyrosin kinases and inhibitory G proteins pathways proceed to the activation of p21ras, a 
molecule that controls a number of cellular processes in the neutrophil, including the 
respiratory burst. Interestingly, not all isoforms of p21ras in neutrophils are activated by 
ANCA. This could possibly allow a specific inhibition of ANCA-activated signalling 
pathways [58]. 
2.1.2.1.4 Apoptosis 
In vitro, TNF -primed neutrophil activation by ANCA results in accelerated and 
dysregulated apoptosis, dependent on reactive oxygen species generation. This 
subsequently leads to impaired phagocyte clearance and secondary necrosis, promoting 
the inflammatory process [59]. In a recent study, MPO-ANCA have been proven a 
stronger apoptosis activator as well as accelerator than PR3-ANCA [60]. Even though 
apoptotic neutrophils cannot undergo cellular activation, they also express MPO and 
PR3 antigens capable of binding by ANCA. Therefore, ANCA can interact with the cell 
surface of apoptotic neutrophils and participate in the opsonization of these cells, 
thereby inducing an increased uptake by macrophages and release of pro-inflammatory 
cytokines. In vivo, these processes might contribute to a failure to regulate inflammation 
in the normal manner [61, 62].  
 
2.1.2.2 In vivo studies  
Despite an increasing number of in vitro observations suggesting the pathogenic 
role of ANCA in vasculitis, there has been a need for in vivo studies to support the 
proposed hypotheses.  
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2.1.2.2.1 MPO-ANCA-associated vasculitis 
In one of the first studies [63], autoimmune-prone rats were immunized with 
human MPO, which led to the development of anti-human-MPO antibodies that cross-
reacted with endogenous rat MPO. A cellular response to MPO could also be detected 
in these rats. Nevertheless, no vasculitic lesions were proven until the MPO-immunized 
rats were injected with an extract of neutrophils, containing MPO, and hydrogen 
peroxide (H202). After this injection, vasculitis of the lungs and the gut occurred, but 
still no glomerulonephritis was found. However, unilateral perfusion of the left kidney 
with the neutrophil extract and H202 induced a severe form of necrotizing crescentic 
glomerulonephritis in MPO-immunized rats and no lesions in non-immunized rats [63, 
64]. Interestingly, immune complex depositions were observed in the kidneys shortly 
after the perfusion but when the glomerulonephritis reached its maximum, immune 
deposits were no longer detected [63]. The degree of histological injury correlated with 
the amount of glomerular IgG immune deposits in a similar model [65].  
On the basis of these experiments, it was concluded that when immune 
complexes are first deposited along the vessel wall, the presence of ANCA can induce 
vasculitis and pauci-immune glomerulonephritis in rats, in other words, that in vivo, 
ANCA play a role in exacerbating and augmenting inflammation initiated by a primary 
stimulus. The presumption that any kind of immune complex deposition along the 
glomerular capillary wall (not necessarily only ANCA/MPO) can enhance local 
immune response in glomeruli was supported by the finding that severe 
glomerulonephritis developed in MPO-immunized rats after low-dose injection of anti-
GBM (glomerular basement membrane) antibodies, but not in the non-immunized ones 
[66].  
More recent experiments [67] involved MPO-deficient mice that, after 
immunization with murine MPO, developed circulating anti-MPO antibodies. Adoptive 
transfer of splenocytes from these mice into recombination activating gene 2 deficient 
(RAG2
-/-
) mice lacking both B and T lymphocytes induced circulating anti-MPO 
antibodies in the recipient mice. All the recipient mice developed renal failure with 
severe crescentic and necrotic renal lesions, but immune complex and complement 
depositions were also observed. Passive transfer of purified anti-MPO IgG into both 
RAG2
-/-
 and wild type mice induced focal necrotizing crescentic glomerulonephritis 
with the lack of immune complexes, closely resembling the human disease. In both 
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adoptive and passive transfer experiments non-glomerular pathology was also noted. 
These data strongly support the pathogenic role of MPO-ANCA in pauci-immune 
glomerulonephritis and systemic vasculitis [67].  
2.1.2.2.2 PR3-ANCA-associated vasculitis 
Contrary to several animal models of MPO-ANCA-associated 
glomerulonephritis and/or vasculitis, a model for PR3-ANCA-associated vasculitis that 
would resemble human Wegener‘s granulomatosis has yet to be developed. Unlike 
human MPO, human PR3 does not elicit a cross-reactive antibody response against 
murine PR3 nor do human PR3-ANCA cross-react with murine PR3 [68]. In a model of 
PR3/elastase deficient mice (double-knockout mice were used since murine PR3 and 
elastase display a highly similar sequence), immunization with murine PR3 led to the 
development of anti-PR3 antibodies, which were able to bind to activated (primed) 
murine neutrophils. After an intradermal injection of TNF , wild-type mice that 
received PR3-ANCA-containing IgG developed a significantly worse form of 
panniculitis than those that received control IgG. However, transfer of PR3-ANCA-
containing IgG into lipopolysaccharide-primed wild type mice did not result in any 
signs of systemic, lung, or renal vasculitis [69]. Whether these experiments provide 
sufficient evidence for a pathogenic effect of PR3-ANCA at local sites of inflammatory 
response has been subject to discussion [68-70].  
 
2.1.2.3 Induction of autoimmunity to antigens recognised by ANCA – 
mechanism and aetiology  
As stated above, ANCA most probably directly participate in the pathogenesis of 
AAV. The truly crucial question, namely, why ANCA develop and what triggers and 
controls their production, remains, however, unclear. Both basic ANCA antigens, i.e. 
MPO and PR3, normally occur in humans. Breaking of self-tolerance is the pivotal 
process in autoimmunity in general. It is well known that autoreactive B and T cells 
exist in the blood of healthy individuals. Nevertheless, control and regulatory 
mechanisms in healthy individuals effectively prevent the development of an 
autoimmune disease [71].  
In AAV patients, both B and T cell function is disturbed. On the whole, different 
environmental and genetic factors are suspected to contribute to the development and/or 
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clinical course of AAV. As for the genetic factors, a number of familial cases of AAV 
have been described. Suggested candidate genes include, among others, those encoding 
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), interleukin-1 receptor 
antagonist (IL-1ra), IL-10, CD18 adhesion molecule and FcγRII/FcγRIII [72-75].  
Regarding the environmental factors, exposure to certain drugs and to silica has 
been associated with AAV. Infection is also long thought to be one of the triggering 
factors in AAV. Previously postulated general mechanisms by which infectious agents 
might induce vasculitis include molecular mimicry, theory of autoantigen 
complementarity, antigen drift, abnormal presentation of self-proteins and/or abnormal 
stimulation of autoreactive B or T cells by e.g. superantigens. In particular the two first 
mentioned mechanisms have lately attracted attention and are therefore described in 
detail below.  
2.1.2.3.1 Antibodies against lysozomal-associated membrane protein 2 (LAMP-
2) and molecular mimicry 
As stated above, several antigenic targets of ANCA different from MPO and 
PR3 have been identified, e.g. lactoferrin, elastase, BPI, lysozomal-associated 
membrane protein 2 (LAMP-2) and others. Clinical significance of ANCA directed 
against these antigens is not completely understood; until recently, they were, however, 
not considered typical for AAV.  
In 2008, Kain et al. [76] showed that antibodies to LAMP-2 were present in 
most (93%) patients with biopsy-proven active pauci-immune focal necrotizing 
glomerulonephritis (FNGN) typical for AAV while only 83% of patients with FNGN 
had ―classical‖ PR3- or MPO-ANCA. Moreover, antibodies to LAMP-2 caused pauci-
immune FNGN when injected into rats, and a monoclonal antibody to human LAMP-2 
caused activation of neutrophils and induced apoptosis of human endothelial cells in 
vitro. The authors also showed that anti-LAMP-2 antibodies recognized an epitope that 
was 100% homologous to the bacterial adhesin FimH, with which they cross-reacted. 
FimH is located at the tip of type 1 fimbriae that is essential for the attachment of Gram-
negative pathogens such as Escherichia coli, Klebsiella pneumoniae and Proteus 
mirabilis to host epithelia. Infection with fimbriated pathogens before presentation of 
FNGN was proven common in the same study (confirmed in 69% individuals).  
Thus, molecular mimicry may be the fundamental mechanism in the 
development of FNGN in AAV. In the context of prior reports, anti-LAMP-2 antibodies 
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might act synergistically with MPO-ANCA to cause pauci-immune glomerulonephritis. 
As LAMP-2 is located on the membranes of intracellular vesicles that contain PR3 and 
MPO, impaired function of LAMP-2 caused by anti-LAMP-2 antibodies might also lead 
to the synthesis of antibodies against cytoplasmic antigens, such as MPO and PR3. [77] 
2.1.2.3.2 Theory of autoantigen complementarity 
Theory of autoantigen complementarity has been suggested as another intriguing 
possible mechanism for the PR3-ANCA production [78]. Complementary PR3 (cPR3) 
is a protein encoded by the anti-sense DNA strand of the PR3 encoding gene. When 
expressed (either from endogenous DNA or from identical genetic material from an 
infectious pathogen), cPR3 might induce development of anti-cPR3-antibodies, which 
might induce anti-idiotype antibodies that would cross-react with the original antigen, 
i.e. PR3. Indeed, some patients with PR3-ANCA have antibodies against cPR3 
translated from the middle portion of the antisense DNA strand of PR3. When mice 
were immunized with cPR3, they produced antibodies not only to cPR3 but also to PR3 
itself (PR3-ANCA). These two types of antibodies did not cross-react and formed an 
idiotypic pair. In line with molecular mimicry mechanism, Staphyloccus aureus, 
Entamoeba histolytica and Ross River virus, pathogens known to be associated with 
PR3-ANCA disease, all contain peptide with an amino acid sequence that mimics the 
cPR3. Although not yet proven, the proposed theory of autoantigen complementarity 
might participate also in the pathogenesis of other autoimmune diseases [79]. 
 
2.2 Pathogenic role of T cells in ANCA-associated vasculitis 
 
As ANCA are mainly IgG antibodies, T-cell-dependent class switch has to occur 
in AAV. Many other findings also support the role of T cells in the pathogenesis of 
AAV and will be summarized in this chapter.  
 
2.2.1 T cells in crescentic “pauci-immune” glomerulonephritis and 
vasculitic lesions 
 
Rapidly progressive, pauci-immune, crescentic necrotizing glomerulonephritis is 
the hallmark of ANCA-associated renal vasculitis. The term ―pauci-immune‖ reflects 
the relative lack of immunoglobulin and complement depositions in affected glomeruli 
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as mentioned above [5].  Given that the effectors of humoral immunity are absent, the 
role of cellular immunity in the process of glomerular injury seems likely. In 
experimental models, delayed-type hypersensitivity (DTH), a manifestation of cell-
mediated immunity induced by sensitized T cells, was shown important for crescent 
formation [80]. In patients with pauci-immune glomerulonephritis, activated T cells, 
macrophages, fibrin, and tissue factor, i.e. mediators of DTH, were prominent at the site 
of glomerular injury [81]. Furthermore, monocytes/macrophages and T cells 
predominate not only in renal but also in pulmonary [82] and nasal infiltrates [83] in 
AAV patients.  
Since particularly PR3-ANCA and not MPO-ANCA associated vasculitis often 
displays granulomatous inflammation typically driven by T cells [84], the important 
role of cell-mediated immunity was supposed mainly in PR3-ANCA-associated disease. 
A recent study, however, also suggests that even in MPO-ANCA-associated 
vasculitis/glomerulonephritis effector T cells contribute to tissue injury as CD4+ T cells 
depletion strongly reduced glomerular crescent formation in an animal model of MPO-
ANCA glomerulonephritis [85]. 
 
2.2.2 MPO- and PR3-specific T lymphocytes 
 
 T lymphocyte proliferation was observed after in vitro stimulation with PR3 
and, to a lesser extent, with MPO in patients with AAV. In these patients, T cells 
proliferate in response to crude granular extract of neutrophils, inactivated purified PR3 
or MPO, and PR3- and MPO-derived peptides. However, similarly as in other 
autoimmune diseases, proliferation was also observed in PR3- or MPO-stimulated 
T cells from healthy controls [86-89]. Whilst an increased frequency of MPO-specific 
T lymphocytes was reported in patients with active MPO-ANCA associated vasculitis 
[88], other authors found no correlation between ANCA titres/activity of the disease, 
and PR3- or MPO-stimulated T cell proliferation [87, 89]. Even though some PR3-
derived peptide sequences were suggested as potential targets of T cell responses in 
AAV, this field clearly requires further studies and the exact role of PR3- and MPO-
specific T cells in the pathogenesis of AAV remains unclear [89-91].  
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2.2.3 T cell activation in AAV 
 
 Several studies found increased serum markers of T cell activation in AAV, 
including soluble IL-2 receptor or soluble CD30. In patients with WG, the levels of 
soluble IL-2 receptor (sIL-2R) correlate well with disease activity [92, 93] and might 
even indicate imminent relapse according to some authors [92] even though this was not 
confirmed by others [94]. Soluble CD30 (sCD30) was also shown to correlate with 
disease activity [94, 95]. Although immunosuppressive treatment leads to a decrease in 
levels of both sIL-2R and CD30, their levels remain increased in comparison with 
healthy controls. Interestingly, increased levels of these soluble markers were associated 
with persistent or renewed ANCA positivity in a recent study, but did not predict a risk 
for relapse [94]. On the basis of these observations, the authors concluded that ANCA 
positivity might relate to a complex, potentially T-cell-driven, immune activation in 
AAV patients.  
 Moreover, in contrast to soluble T cell markers and to activation markers on 
B lymphocytes, activation markers on T cells (e.g. CD25 and HLA-DR) seem not to 
correlate with disease activity; they are up-regulated even in remission and despite 
treatment [96, 97]. In a recent study, this phenomenon called persistent T cell activation 
(defined as either increase in CD25+ naïve CD4+ lymphocytes and/or decrease in the 
total number of CD4+CD45RO  naïve cells) was shown to be associated with disease 
severity [98]. 
  
2.2.4 T cell subpopulations in AAV 
 
A number of different T cell subpopulations with presumed regulatory, effector 
and/or helper functions have been described during the last decade. Based on the 
cytokines and co-stimulatory signals involved, a naïve T cell can follow several 
differentiation pathways (some of them portrayed in Fig. 2.2). It is, however, necessary 
to stress that this area has been undergoing rapid development and completely novel 
pathways might be described in the near future.  
Dysregulation of immune pathways has been hypothesized to play role in many 
autoimmune diseases, including AAV. The most often discussed subpopulations of 
T cells in AAV, i.e. regulatory T cells, T helper cells type 1 and 2 (Th1/Th2), recently 
described Th17 cells, and effector memory T cells, will be mentioned in detail below. 
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Fig. 2.2: Different ways of naïve T cell differentiation. Th = T helper cells, Treg = regulatory T 
cell, Tr1 = a subset of regulatory T cells, TGF-  = transforming growth factor-beta. For other 
abbreviations see text. 
 
2.2.4.1 Regulatory T cells in AAV 
 In general, several mechanisms might contribute to T cell activation in AAV, 
e.g. aberrant co-stimulation or expression of co-stimulatory molecules, or homeostatic 
expansion [99]. Nevertheless, special emphasis was placed on the role of regulatory 
T cells (Tregs) in AAV in the last few years. Tregs are a subset of CD4+ T cells, 
characterised by a high-level surface expression of CD25
 
and intracellular expression of 
the transcription factor forkhead box P3 (FoxP3) [100]. Decreased frequency and/or 
impaired function of Tregs have been described in several autoimmune diseases, e.g. 
multiple sclerosis [101], rheumatoid arthritis [102] and systemic lupus erythematosus 
[103]. Until recently, no difference in the numbers or function of Tregs had been 
described in AAV [97, 99].  Contrary to previous findings, Abdulahad et al. [104] 
reported on expanded proportion of Tregs that poorly suppressed CD4+CD25  effector 
T cell proliferation in patients with WG in remission. Such a functional defect of Tregs 
might support the development of inflammation and autoimmunity in WG but data from 
animal and further in vitro studies are still needed [105]. 
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2.2.4.2 Th1/Th2 paradigm in AAV 
Based on their cytokine profile and related ability to generate different types of 
immune effector responses, CD4+ T helper lymphocytes used to be classified into two 
distinct subsets: type 1 (Th1) and type 2 (Th2) (Figure 2.3). In general, Th1 cells 
characteristically produce interferon gamma (IFNγ) and are involved in cell-mediated 
inflammatory reactions. They promote macrophage activation and delayed-type 
hypersensitivity (DTH). Th2 cells, producing interleukin (IL)-4, IL-5, IL-10 and IL-13, 
are associated with phagocyte-independent host responses, encourage non-complement-
fixing IgG and IgE production and enhance eosinophil proliferation and function. [106, 
107] 
 
 
Fig. 2.3: Th1/Th2 differentiation, associated cytokines and surface molecules [adapted from 
108]. For abbreviations see text. 
 
 Both Th1 and Th2 cells differentiate from naïve precursors (Th0) following 
specific antigen stimulation via their /  T cell receptor (TCR). Antigen dose and 
antigen affinity can influence Th subset development. The key factor in directing Th 
cell polarization is the cytokine milieu but co-stimulatory signals are also important. 
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The main inducers of the Th1 profile are IFNγ and IL-12.  In recent years, IL-18 and IL-
27 have been recognized as promoters of Th1 polarization. IFNγ but not IL-12 may 
participate in inhibiting Th2 responses [109]. Of the Th2-related cytokines, IL-4 
promotes differentiation of naive CD4+ cells into Th2 cells, whereas IL-10 inhibits Th1 
cytokine synthesis. As for the co-stimulatory molecules, CD80 and CD86 signal via 
CD28, constitutively expressed on T cells. Inhibition of CD28 blocks Th2 responses 
without blocking Th1 responses [110].  
 Differences in surface membrane markers on Th1 and Th2 cells subsequently 
result in different intracellular signalling events. In addition, Th1 and Th2 cells seem to 
express different patterns of chemokine receptors. CXCR3, the receptor for IFNγ 
inducible chemokines (e.g. IP-10, Mig and I-TAC), and CCR5 are predominantly 
expressed at high levels on Th1 cells. On the other hand, CCR3 and CCR4 are 
associated with Th2 cells [111].  
The Th1/Th2 paradigm in AAV, in particular in WG, has been discussed 
recently in many studies [95, 112-121, 123].  In localized WG, i.e. early WG restricted 
to the respiratory tract, T cells in nasal inflammatory infiltrates were shown to 
abundantly express CD26, an optional Th1 marker. In the same study, higher numbers 
of IFNγ-positive cells in localized WG than in generalized disease were found both in 
nasal infiltrates and in peripheral blood. On the contrary, IL-4 mRNA was detected in 
higher amounts in nasal biopsies in generalized WG [112]. Th2 environment in nasal 
granuloma in generalized WG was also detected in another study [113], in which 
increased IL-4 expression but no IFNγ were observed in nasal biopsies in generalized 
active WG.  
Both localized and generalized WG displayed up-regulated expression of both 
Th1-associated CCR5 and Th2-associated CCR3 chemokine receptors in a flow 
cytometric analysis of circulating T cells. Nevertheless, predominant CCR5 expression 
on T cells as well as in granulomatous lesions was noted in localized WG, which may 
favour stronger recruitment of Th1-cytokine-secreting cells into inflammatory lesions 
[114, 115].  
As mentioned above, plasma levels of sCD30, a member of the tumour necrosis 
factor receptor family and a Th2 marker, have been shown to be significantly increased 
and to correlate with disease activity in generalized WG. These findings further support 
the hypothesis that generalized WG may be associated with Th2 type of immune 
response [95].  
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 In summary, there seems to be an aberrant Th1 type response that might play 
role during initiation of WG in patients with localized WG, when PR3 is often not yet 
detected. On the contrary, there seems to be significant appearance of Th2 cells and less 
prominent Th1 phenotype and Th1 cytokine production in granulomatous lesions of the 
upper respiratory tract (and eventually also in peripheral circulation) in patients with 
generalized vasculitis. This increasing complexity and ―shift‖ of immune response have 
been hypothesized to be a consequence of B cell expansion and T cell dependent PR3-
ANCA production during disease progression [116], potentially triggered by interaction 
between neutrophils and autoreactive T and B cells within granulomatous lesions. 
Persistent antigenic stimulation, e.g. by Staphylococccus aureus (a known risk factor for 
relapse in WG [32]), might contribute to the shift in the immune response [117]. 
Nevertheless, data regarding the type of Th response in WG are not entirely 
consistent. Predominant IFNγ production by T cells from peripheral blood, 
bronchoalveolar lavage, and granulomatous nasal lesions was reported in patients with 
generalized WG [118]. Furthermore, in renal lesion of the patients with generalized 
AAV, the polarization towards Th1 type response was found but the lesions contained 
Th2 cells as well [113, 119, 120].  
Increased IFNγ production in WG patients was noted in another study, possibly 
induced by increased amounts of IL-12, produced by monocytes in both active and 
inactive patients with WG. Moreover, the authors demonstrated that in vitro IFNγ 
production might be inhibited by exogenous IL-10 [121]. In addition to its presumed 
association with Th2 type of immune response, IL-10 is a cytokine with 
immunosuppressive and anti-inflammatory potential. Levels of IL-10 were high at 
diagnosis in patients with WG and decreased subsequently. Intriguingly, low levels of 
IL-10 were associated with increased relapse rate in a recent study [94]. Polymorphisms 
in genes for IL-10 associated with WG have already been described [122].  
Even though less thoroughly studied, Th2 immune response was reported in 
CSS, where T cells producing IL-4 and IL-13 may drive the eosinophilic inflammation 
[123]. Only little information is available on the Th1/Th2 polarization in MPA.  
2.2.4.3 Th17 lineage in Wegener’s granulomatosis 
Nowadays, it is obvious that apart from Th1 and Th2 cells other subsets of 
T helper cells can be defined. The recently described IL-23-dependent-IL-17-producing 
  
27 
CD4+ T helper cell subset has been termed Th17 lineage. The Th17 immune pathway 
has been hypothesized to play an evolutionary significant role in rapid recruitment of 
neutrophils to the sites of acute infection [124]. This rapid response likely serves to 
―wall-off‖ the damaged tissue and presumably ―buys time‖ for the induction of 
antimicrobial Th1-IFN  response which takes several days to develop. If dysregulated, 
the Th17 pathway might lead to the development of a chronic inflammatory response 
and thus participate in the pathogenesis of various autoimmune diseases [124].  
In patients with WG, a skewed Th17 response that suggests the role of IL-17 in 
the disease pathogenesis has recently been proven by Abdulahad et al. [125] but further 
studies are needed to clarify the significance of the Th17 lineage in AAV.  
2.2.4.4 The role of effector memory T cells in AAV 
Numerous studies have given attention to the altered phenotype of T cells in 
AAV, especially in WG. The expansion of a subset of circulating T cells lacking co-
stimulatory molecule CD28 has been reported repeatedly [126-129]. However, 
surprisingly very little is still known about this immunological phenomenon.  
The expansion of CD28– T cells starts early in the disease process and correlates 
with organ involvement and disease progression from localized to generalized WG 
[127, 128]. Most studies show that circulating peripheral blood CD4+CD28– T cells as 
well as those within granulomatous lesions are a major source of Th1 cytokine secretion 
[128]. Moreover, expanded CD28– T cells express the differentiation marker CD57, the 
activation marker and adhesion molecule CD18, Th1 type chemokine receptor CCR5, 
and upregulate HLA-DR and CD152 (CTLA-4), which indicates that these cells belong 
to so-called late differentiated or effector memory T cells (TEMs) [126-132]. Shortened 
telomers and oligoclonality indicate cytokine- and/or antigen-driven expansion and 
replicative senescence of TEMs [133, 134].  
Intriguingly, patients in remission display higher levels of circulating TEMs than 
patients with active disease. It is speculated that these TEMs migrate from peripheral 
blood to the sites of inflammation causing a decrease in circulating memory T cells 
during active disease [135]. 
As proliferation of T cells toward TEMs requires a strong and persistent immune 
trigger, presence of such an antigenic stimulus in WG patients seems likely. Contrary to 
central memory T cells, TEMs do not express CCR7, the lymph node homing receptor, 
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and thus fail to migrate to lymphoid organs (Figure 2.4). However, they are capable of 
migrating to the sites of inflammation and producing pro-inflammatory cytokines [131].  
 
 
Fig. 2.4: Two types of memory T cells with different migration preferences [adapted from 136] 
 
The apoptosis process was proven impaired in CD28– TEMs due to increased 
expression of anti-apoptotic protein Bcl-2 [137]. Although not yet proven, CTLA-4 
could contribute to this Bcl-2 increased expression. In addition, the aforementioned 
defective function of Tregs in WG may also account for TEMs expansion [104]. Last but 
not least, two recently identified T-cell-function-associated genetic factors predisposing 
to granulomatous inflammation (HLA-DPB1*0401) and PR3-ANCA positivity 
(PTPN22*620W) might be related to both persistent T cell activation and TEMs 
expansion in WG [138, 139]. 
Taken together, Th1 type TEMs might contribute to the chronic granulomatous 
inflammation and development of autoimmunity in WG.  In accordance with previous 
findings regarding the Th1/Th2 concept, exaggerated Th1 response in the respiratory 
tract with clonal expansion of TEMs could sustain the chronic granulomatous 
inflammation and promote the formation of ectopic ―lymphoid-like‖ tissue within 
granulomatous lesions. Subsequently, this might induce PR3-ANCA formation which 
results in ANCA-induced vasculitis [132]. Therefore, suppression of TEMs cells might 
become an important goal in therapeutic strategies in AAV in the future.  
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2.3 Therapeutic implications 
 
Without treatment, the prognosis of systemic AAV is poor. In 1958, the average 
patient survival after diagnosis of WG was 5 months [140]. The unfavourable outcome 
of patients with AAV was dramatically improved in the early 1970s when Fauci and 
Wolff introduced an empirical therapeutic scheme consisting of daily oral 
cyclophosphamide (CYC) and corticosteroids administered for at least one year [141]. 
Thus, remission was induced in approximately 80% of cases [142]. However, the 
toxicity of the regimen caused considerable morbidity and mortality [142]. Moreover, 
a long-term follow-up showed that at least 50% of the patients relapsed, even under 
continuing immunosuppression, or when the therapy was reduced [143]. 
 Therefore, there has been an urgent need to find new effective treatment 
strategies and modalities with lower toxicity. Such an approach has been lately 
supported by major advances in understanding the disease pathogenesis. At present, 
remission induction treatment of AAV may involve pulsed cyclophosphamide, 
methotrexate or plasma exchange, according to disease severity. Azathioprine was 
proven successful for remission maintenance therapy. Newer promising therapeutic 
possibilities include mycophenolate-mofetil, deoxyspergualin or leflunomide.  
Development of biological therapy has revealed a completely new area of 
therapeutic options in AAV. At present, biologics are still used more as a rescue therapy 
after conventional therapeutic regimens have failed. Nevertheless, in the oncoming 
years they are likely to play a more important role in the therapy of AAV and are 
therefore mentioned in detail below. 
 
2.3.1 Biological therapy in ANCA-associated vasculitis 
 
Biologics currently used in AAV include intravenous immunoglobulins, anti-
thymocyte globulin, alemtuzumab, and mainly rituximab and anti-TNFα therapy. 
A number of studies have reported the beneficial effects of intravenous 
immunoglobulin (IVIg) in patients with chronic grumbling vasculitis not reacting to 
conventional treatment or in patients with acute disease. Jayne et al. [144] conducted a 
small controlled trial of IVIg given as a single course of a total dose of 2 g/kg in 
patients with chronic active disease. This treatment resulted in a significant clinical 
improvement, but the effect was short-lived and did not last beyond 3 months.  
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As for anti-T-cell-directed biologics, fifteen patients with active refractory WG 
were treated with anti-thymocyte globulin (ATG) in a trial designed by the European 
Vasculitis Study Group (EUVAS). Thirteen of 15 patients showed a favourable 
response to ATG. While the authors conclude that anti-T-cell-directed treatment with 
ATG may be a therapeutic option for severe refractory Wegener's granulomatosis, they 
at the same time warn that the therapy is, however, associated with a high risk of 
infection and toxicity, and the risk-to-benefit ratio always needs to be considered [145].  
Rituximab (RTX) is a genetically engineered chimeric monoclonal antibody that 
contains a human IgG1 constant region plus murine heavy and light chain variable 
regions directed against CD20. Rituximab causes a selective transient depletion of the 
CD20+ B cell subpopulation (i.e. the whole B cell population with the exception of 
plasma cells and pre-B cells), which typically lasts for at least 6 months with subsequent 
gradual reconstitution of B cell numbers. Elimination of B cells by RTX (4 weekly 
doses of 375 mg/m2 or, occasionally, 2 doses of 1g 2 weeks apart) successfully induced 
complete but temporary remissions in patients with AAV refractory to conventional 
therapy in several smaller studies [146, 147]. However, some patients, especially those 
with predominantly granulomatous manifestations, seem not to respond to RTX [148]. 
Rituximab therapy was usually accompanied by prednisolone, and the previous 
immunosuppressive therapy with cytotoxic agents was also often continued. Safety did 
not appear to be a major problem but continued vigilance is warranted. Repeated 
rituximab administration was suggested and proven successful after B cell 
reconstitution but human anti-chimeric antibodies (HACA) and prolonged 
hypogammaglobulinaemia might occur [149]. Randomised controlled studies are 
needed to clarify the effects of RTX and its indication in AAV. 
The expansion of circulating TNFα-producing Th1 type CD28– effector memory 
T cells and their presence as Th1-type-cytokine-profile-driving cell population within 
granulomatous lesions, together with further in vitro data supporting the role of TNFα in 
the pathogenesis of AAV, provide the rationale for using TNFα-blocking agents in 
refractory AAV. Both the chimeric monoclonal anti-TNFα antibody infliximab and the 
fusion protein consisting of a part of the human TNFα receptor linked to the Fc portion 
of human IgG1 etanercept have been successfully applied as additional therapy for 
refractory Wegener‘s granulomatosis in smaller studies [150, 151]. Nevertheless, 
relapses were quite common and some severe infectious complications were noted. 
The randomised WGET trial (Wegener‘s Granulomatosis Etanercept Trial), in 
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which patients were randomised to receive either etanercept or placebo in addition to 
standard immunosuppressive treatment, did not, however, confirm the efficacy of 
etanercept [152]. The time to remission, duration of remission or relapse rate did not 
differ between the groups. Intriguingly, 6 patients in the etanercept group developed 
solid organ cancers [153]. On the contrary, no cancer was observed in the placebo group 
even though the patients were also treated with CYC.  
Despite the lack of efficacy of etanercept in the therapy of AAV, it is still 
possible that TNFα blockade with infliximab might be beneficial in the induction 
therapeutic regimens in AAV, which has to be clarified in future controlled trials. While 
etanercept binds to circulating TNFα only, infliximab also binds to TNFα complexed 
with TNFα receptors and might therefore have a different therapeutic mechanism. As in 
inflammatory bowel disease [154], infliximab but not etanercept may therefore be 
proven useful in the therapy of AAV. 
Lymphocyte depletion using humanized monoclonal anti-CD52 antibodies 
(alemtuzumab) has been reported in a series of patients with relapsing/refactory disease. 
Although most patients achieved remission, relapses and adverse events were common 
in the long run and further studies are needed [155].  
 
2.3.2 Therapeutic trends for the future 
 
 
 Many monoclonal antibodies to molecules involved in the disease pathogenesis 
have already been developed.  For instance, interaction of CD28 on T cells with CD80 
and CD86 on antigen-presenting cells is required for T cell activation. As CTLA-4 
(cytotoxic T-lymphocyte-associated antigen 4, receptor for both CD80 and CD86) is 
upregulated on effector memory T cells in WG, blocking of CTLA-4-mediated co-
stimulation and upregulation of anti-apoptotic Bcl-2 expression by CTLA-4-
immunoglobulin (Abatacept) might help to modulate pathologic immune response in 
AAV [104].  
Another therapeutic approach might, for instance, target Kv1.3 K+ channels, 
which are specific functional markers of TEMs.  In rat models of rheumatoid arthritis, 
specific Kv1.3 blockers have already been successfully used [156]. In the future, 
monoclonal antibodies inhibiting e.g. endothelium-neutrophil interactions, ANCA or 
directly suppressing signalling cascades triggered by ANCA could be developed and 
once even terminate the need for cytotoxic therapeutic regimens in AAV.  
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3. MATERIAL AND METHODS 
3.1 Patient characteristics 
3.1.1 Basic cohort of patients 
 
A total of 69 patients with AAV, followed-up at the Department of Nephrology, 
General Teaching Hospital and First Faculty of Medicine, Charles University in Prague, 
were originally included into this flow cytometric study during a 16-month period 
(September 2004 - December 2005). The basic characteristics of the patients are 
summarized in Table 3.1. 
 
Table 3.1: Patient characteristics at the time of inclusion into the study (No. of patients = 69) 
Characteristics                           Data
1  
                              
Age (years)  56 (22-76) 
Male gender                           40 (58%) 
Type of vasculitis                          
 
 
 
WG 
MPA 
RLV 
CSS 
 
 39 (56.5%) 
 19 (27.5%) 
   9 (13%) 
   2 (3%) 
ANCA specificity 
 
   
PR3-ANCA 
MPO-ANCA                        
 
 42 (60.9%) 
27 (39.1%) 
Duration of vasculitis before inclusion (months)                   15 (0-168) 
Organ involvement (anytime in patients‘ history)        
 68 (98.5%) 
 36 (52.2%) 
 25 (36.2%) 
 Kidney 
Lungs 
ENT 
Serum creatinine (µmol/L) 173 (46-602) 
No. of patients on haemodialysis 14 (20.3%) 
1
Data are presented as No.(%), or median (range).  
 
Patients with WG, MPA and CSS matched the definitions for those diseases as 
formulated by the Chapel Hill Consensus Conference [4]. Patients with WG and CSS 
  
33 
also met the American College of Rheumatology criteria [3]. The diagnosis of renal-
limited vasculitis (RLV) was based on renal biopsy showing focal or diffuse segmental 
necrotizing crescentic glomerulonephritis and absence or paucity of immune deposits by 
immunofluorescence, together with the lack of other systemic manifestations of 
vasculitis.  
Disease activity was documented with the use of Birmingham Vasculitis 
Activity Score (BVAS) in its BVAS2003 modification [157], based on clinical 
observations and laboratory results performed routinely at patients‘ regular visits to the 
clinic.  
The patients‘ initial status was classified as: 
o remission – in 36 patients; defined as the absence of clinical signs and 
symptoms of active vasculitis, irrespective of ANCA levels, BVAS=0; or 
o active disease – this group of patients consisted of:  
 newly diagnosed patients - 20 patients; diagnosed ≤ 6 weeks 
before inclusion into the study, 
 patients with chronic grumbling disease - 9 patients; 
BVAS=1-5, with no signs of new or worse disease, and 
 patients with relapse - 4 patients; defined as clinical signs of 
new or worse disease activity in combination with laboratory 
results reflecting disease activity and/or new/worse finding on 
imaging methods compatible with disease activity, BVAS>1. 
All patients were subsequently monitored up until May 2008 at their regular 
visits to the clinic. Clinical status, BVAS, ANCA levels, renal parameters, relapses and 
deaths were registered.  
Blood samples (a total of 12 millilitres of venous blood in several different 
collection tubes) were collected from each patient at entry. Ongoing infection in the 
patients was ruled out. Occasionally, some of the patients were examined repeatedly 
when either their disease relapsed or, on the contrary, they achieved remission. Thus, a 
total of 94 analyses of peripheral blood samples of 69 patients with AAV were 
performed. The repeated samples were included only in the subgroup analysis of AAV 
patients but not in the basic comparison (i.e. within each subgroup all patients are 
unique). A total of 43 patients were examined in the active phase of the disease (20 
patients with newly diagnosed disease, 9 patients with chronic grumbling disease and 
14 patients with relapse). Fifty-one patients were examined in remission. Table 3.2 
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shows clinical characteristics of patients in each subgroup. Patients with chronic 
grumbling disease were later excluded from the subgroup analysis due to their low 
number.  
 
Table 3.2: Clinical characteristics of patients in subgroups according to disease activity (at the 
time of blood sample examination) 
 Newly 
active 
Chronic 
grumbling 
Relapse Remission 
No. of patients 20 9 14 51 
Male gender
1
 14 (70%) 7 (77.8%) 8 (57.1%) 26 (51%) 
Age (years)
2
 58 (24-73) 49 (30-65) 52 (22-68) 57 (27-76) 
PR3-ANCA/MPO-ANCA
3
 10/10 9/0 13/1 29/22 
S-creatinine ( mol/L)
2
  255.5 (46-602) 147 (81-401) 153 (54-512) 148 (54-298) 
No. of patients on 
haemodialysis
1
 
4 (20%) 2 (22.2%) 3 (21.4%) 7 (13.7%) 
ANCA (ELISA–IU/mL4)2 74 (9->100) 35 (7->100) 38 (11->100) 0 (0-82) 
BVAS
2
 25.5 (10-44) 2 (1-5) 16 (6-23) 0 
Data presented as 
1 
No. (%) or as 
2 
median (range). 
3
 Anytime in patients‘ history. 4 Normal range 0-5. 
PR3 = proteinase 3, MPO = myeloperoxidase, BVAS = Birmingham Vasculitis Activity Score.  
 
Clinical characteristics of the subgroups of patients with PR3-ANCA and MPO-
ANCA-associated disease are summarized in Table 3.3. 
 
Table 3.3: Clinical characteristics of patients with PR3-ANCA- and MPO-ANCA-associated 
disease 
 PR3-ANCA MPO-ANCA 
No. of patients 42 27 
Male gender
1
 25 (59.5%) 15 (55.6%) 
Age (years)
2
 54 (22-72) 62 (24-76) 
S-creatinine ( mol/L)
2
  148 (46-538) 209 (54- 602) 
No. of patients on haemodialysis
1
 9 (21.4%) 5 (18.5%) 
No. of samples examined 
                            Active disease 
                            Remission 
60 
       32 
       28 
34 
       11 
       23 
Data presented as 
1 
No. (%) or as 
2 
median (range). PR3 = proteinase 3, MPO = myeloperoxidase. 
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Induction immunosuppressive treatment consisted of corticosteroids (usually 
started with 3 pulses of intravenous methylprednisolone, then continued with oral 
prednisolone) and cyclophosphamide (either oral or intravenous pulse) in all newly 
active patients. In patients with severe disease, adjunctive therapy with plasma 
exchange was prescribed. After 3 months of stable remission, the patients were 
switched to azathioprine or mycophenolate-mofetil for at least 18 months. Relapses 
were treated with regard to their severity and patients‘ history (e.g. new series of pulsed 
cyclophosphamide; addition or change of an immunosuppressive drug; increase in dose 
of respective immunosuppressive agent and/or corticosteroids). Patients treated with 
biological therapy (i.e. rituximab) were analysed separately (see below).  
In this study, a total of 10 active patients (8 newly diagnosed patients and 2 
patients with relapse) were examined before any immunosuppressive therapy was 
administered. Sixteen remission samples were collected from patients in whom the 
immunosuppressive therapy had been stopped before. 
The control group consisted of 30 healthy volunteers or blood donors (16 men, 
14 women; median age 53 years, range 23-81 years). While surface molecules were 
examined in all healthy controls, results on the intracellular cytokine production were 
available in 24 out of 30 healthy individuals only (13 men, 11 women; median age 54.5 
years, range 23-81 years).  
Another control group of 20 patients with chronic kidney disease caused by 
―non-immunological‖ conditions such as hypertensive or diabetic nephropathy (13 men, 
7 women; median age 59 years, range 24-83 years; median serum creatinine 181 
mol/L; 4 patients on haemodialysis, 1 patient treated with peritoneal dialysis) was also 
examined in this study. 
Biochemical and haematological tests, and ANCA testing were performed in 
routine laboratories of the General Teaching Hospital in Prague. ANCA were 
determined by both IIF and ELISA (Orgentec, Mainz, Germany). The design of the 
work conformed to currently applied ethical standards.  
3.1.1.1 Long-term follow-up of the basic cohort of AAV patients - 
clinical characteristics  
During the follow-up (median time 43 months, range 1-44), 28 out of 69 patients 
relapsed (40.6%). The median time to relapse was 19 months (range 2-38 months) after 
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the inclusion into the study. Out of 51 patients who were examined in remission, relapse 
was observed in 19 patients. Clinical characteristics of patients with and without relapse 
are summarized in Table 3.4.  
 
Table 3.4: Clinical characteristics of patients in remission without and with relapse during the 
follow-up (at the time of blood sample examination) 
 Without relapse With relapse 
No. of patients 32 19 
Male gender
1
 18 (56.3%) 10 (52.6%) 
Age (years)
2
 57.5 (27-76) 57 (33-71) 
PR3-ANCA/MPO-ANCA
3
 18/14 11/8 
S-creatinine ( mol/L)
2
  163 (54-260) 147 (79-298) 
No. of patients on hemodialysis 5 (15.6%) 2 (10.5%) 
ANCA (ELISA–IU/mL4)2 0 (0-48) 0 (0-82) 
Data presented as 
1
No. (%) or as 
2
median (range). 
3Anytime in patients‘ history. 
 
4
Normal range 0-5. PR3 = proteinase 3, MPO = myeloperoxidase. 
 
Eight out of 69 patients died (11.6%) during the follow-up. The cause of death 
was attributable to active disease in 4 patients. In 2 patients the death was related to 
infectious complications of immunosuppressive therapy. One patient died of lung 
cancer; the influence of previous long-term immunosuppressive treatment cannot be 
excluded. In the last patient, the death was caused by heart failure, and related neither to 
vasculitis nor its treatment.  
 
3.1.2 Patients treated with rituximab  
 
One of the aims of this work was to monitor the influence of administered 
biological therapy on the lymphocyte subpopulations and intracellular cytokine 
production. From August 2005 to June 2007, rituximab (RTX) was administered to 6 
patients with AAV (for their basic characteristics see Table 3.5). In 4 patients with 
refractory disease 2x1 g of RTX two weeks apart was administered. Two newly 
diagnosed patients were treated with 4x 375 mg/m2 of RTX weekly. In all cases, RTX 
administration was accompanied by 2 pulses of cyclophosphamide and corticosteroids. 
Blood samples (5 mL of venous blood) were examined regularly at 0-1.5-3-6-9-12-18-
24 months after RTX administration. In March 2009, the median time of follow-up of 
the patients was 36 months (range 21-42 months). 
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Table 3.5: Characteristics of the patients with AAV treated with rituximab (No. of patients = 6) 
Characteristics                           Data
1  
                              
Age (years)  42.5 (36-74) 
Male gender                           5 (83.3%) 
Type of vasculitis                          
 
 
 
WG 
MPA 
RLV 
 
 4 (66.7%) 
 1 (16.7%) 
 1 (16.7%) 
ANCA specificity 
 
   
PR3-ANCA 
MPO-ANCA                        
 
 4 (66.7%) 
2 (33.3%) 
Duration of vasculitis before inclusion (months)                   43 (0-150) 
Organ involvement (anytime in patients‘ history)        
 4 (66.7%) 
 3 (50%) 
 1 (16.7%) 
 Kidney 
Lungs 
ENT 
Serum creatinine (µmol/L) 195 (76-350) 
No. of patients on hemodialysis 1 (16.7%) 
1
Data presented as No.(%), or median (range). ENT = ear, nose and throat. 
 
3.2 Media, reagents and antibodies 
 
For flow cytometric analyses of cell surface markers and intracellular cytokines 
the following material was used: 
 
Tubes: 
- BD Vacutainer 5mL blood collection tubes with Natrium Heparin (BD 
Biosciences, San Jose, CA, USA) 
- Polypropylene tubes for blood cell cultivation (Nunc, Thermo Fisher 
Scientific, Rochester, NY, USA) 
- BD Falcon tubes 12x75 mm for cell staining (BD Biosciences) 
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Reagents for cell cultivation and stimulation: 
- RPMI „Roswell Park Memorial Institute― medium 1640 (Gibco, Invitrogen, 
Carlsbad, CA, USA) 
- Brefeldin A (BFA) – transport inhibitor protein; reconstitued and diluted, 
used at a final concentration of 10 g/mL (Sigma Aldrich, St.Luis, MO, 
USA)  
- Phorbol 12-myristate 13-acetate (PMA) – mitogen; reconstitued and diluted, 
used at a final concentration of 20 ng/mL (Sigma Aldrich) 
- Ionomycin – ionophore; reconstitued and diluted, used at a final 
concentration of 1 g/mL (Sigma Aldrich) 
- Lipopolysaccharide (LPS) – mitogen; reconstitued and diluted, used at a 
final concentration of 1 g/mL (Sigma Aldrich) 
- Phytohaemaglutinin  (PHA) – reconstitued and diluted, used at a final 
concentration of 1 g/mL (Wellcome, Dartford, England) 
 
Monoclonal antibodies – directly conjugated with a fluorochrome: 
 BD Biosciences: 
 CD4-PerCP (peridinin 
chlorophyll protein) 
 CD19-PerCP 
 CD80-PE 
(phycoerythrin) 
 CD86-PE 
 CD3-FITC (fluorescein 
isothiocyanate) 
 CD3-PerCP 
 HLA-DR-PE 
 CD45RA-FITC 
 CD28-PE 
 CD30-PE 
 CCR5 (chemokine 
receptor 5) -PE  
 CD14-FITC 
 TNFα-FITC  
 IL-2-PE  
 IFNγ-FITC 
 IL-4-PE 
 IL-10-PE 
 IL-12-PE  
 CD20-APC 
(allophycocyanin) 
 
 
 
Immunotech – Beckman Coulter (Fullerton, CA, USA) 
 CRTH2 (chemoattractant receptor-homologous molecule 
expressed on Th2 lymphocytes)-PE 
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R&D (Minneapolis, MN, USA)  
 CXCR3 (CXC chemokine receptor 3)-FITC 
 
Other material: 
- FACS Permeabilizing Solution  (BD Biosciences) 
- FACS Lysing Solution (BD Biosciences) 
- Washing solution: CellWASH (BD Biosciences) 
- Fixative solution: CellFIX (BD Biosciences) 
 
Analysis equipment: 
- FACSCalibur (Fluorescence Activated Cell Sorter) with G3 Macintosh 
computer (BD Biosciences) + CellQuest software (BD Biosciences) 
- FACSCanto (BD Biosciences) + BD FACSDiva 5.03 (BD Biosciences) – 
since 2007 
 
3.3 Flow cytometry 
3.3.1 Intracellular cytokine production 
3.3.1.1 Cell activation 
 In this study, a previously described and validated modification [158] of the 
commonly used procedure for cell activation was applied. In routine laboratory practice, 
this modification enables to examine blood samples delivered to laboratory during the 
whole day (and not only in the early morning hours as required for the common 
procedure). 
3.3.1.1.1 Lymphocyte cultivation 
1. 500 L of RPMI 1640 + 10 L of PHA with 500 L of whole peripheral 
blood pipetted into the cultivation tube. 
2. The tube inserted into the incubator (at temperature 37°C under 5% CO2) 
for 20-22 hours. 
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3. Afterwards, 10 L of BFA + 10 L of PMA + 10 L of ionomycin added 
into the tube.  
4. The tube inserted into the incubator (at temperature 37°C under 5% CO2) 
for 4.5 hours. 
3.3.1.1.2 Monocyte cultivation 
1. 10 L of LPS with 500 L of whole peripheral blood pipetted into the 
cultivation tube. 
2. The tube inserted into the incubator (at temperature 37°C under 5% CO2) 
for 20-22 hours. 
3. Afterwards, 10 L of BFA added into the tube. 
4. The tube inserted into the incubator (at temperature 37°C under 5% CO2) 
for 4.5 hours. 
3.3.1.2 Procedure for intracellular cytokine determination 
1. 100 L of cultivated blood (see above)  + 20 l of monoclonal antibody 
directed against surface antigens incubated for 20 minutes in the dark at 
room temperature. 
2. Erythrocytes lysing and lymphocyte fixing: Lysing solution (2 mL) added, 
incubated for 10 minutes in the dark at room temperature. Centrifugation 
(1,000 rpm for 5 minutes) followed, supernatant poured off afterwards.  
3. 500 l of permeabilizing solution added, incubated for 10 minutes in the 
dark at room temperature. Washing solution added, centrifugation 
followed, and supernatant poured off afterwards. 
4. 20 l of respective monoclonal antibody against intracellular antigen added, 
incubated for 25 minutes in the dark at room temperature. Afterwards, the 
samples washed twice.  
5. Intracellular cytokines analysis by flow cytometer. T lymphocytes gated 
using FSC (forward scatter) and CD3; monocytes gated using SSC (side 
scatter) and CD14.  
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3.3.2 Cell surface marker staining 
 
Whole peripheral blood samples were incubated in the presence of respective 
monoclonal antibodies in the dark at room temperature (20-25 °C) for 15 minutes. After 
the lysing and washing phases, three-colour flow cytometric analysis was performed by 
FACSCalibur (six-colour analysis enabled by FACSCanto since 2007).  
Basic subpopulations of lymphocytes (CD3, CD4, CD8, CD19, CD16 and 
CD56) were determined by a routine flow cytometric laboratory procedure, using the 
BD Biosciences monoclonal antibodies and equipment. 
 
3.4 Statistical analysis 
 
Statistical analysis was performed applying SPSS and STATGRAPHICS Plus 
software. Continuous variables are presented as mean ± standard deviation or as median 
with range. Differences in continuous variables were compared by means of Student‘s t-
test in the case of normal distribution. Otherwise, the Wilcoxon signed rank test was 
used for comparison of paired data, and the Mann-Whitney test for comparison of 
unpaired data. For multiple comparisons, the non-parametric Kruskal-Wallis test, or 
ANOVA with further analysis using Tukey‘s method were used. Proportions between 
two groups were compared with Fisher‘s exact test or, for larger samples, with chi-
square test. The correlation analysis was performed using the non-parametric 
Spearman‘s test. A two-sided P <0.05 was considered statistically significant in all 
cases.  
The statistical analysis was performed by and the results consulted with 
statisticians from the National Institute of Public Health and from the Department of 
Statistics and Probability, Faculty of Informatics and Statistics, University of 
Economics. 
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4. RESULTS 
4.1 Basic cohort of patients with AAV  
4.1.1 Surface molecules 
 
 The absolute number of lymphocytes was significantly reduced in patients with 
AAV (both in patients with active disease and in patients in remission) when compared 
to healthy controls (HC, p<0.001, Table 4.1). In contrast to the absolute numbers of 
lymphocytes, the percentage of CD3+ cells (T lymphocytes) did not significantly differ 
between AAV and HC.  
 
Table 4.1: Lymphocyte levels in patients with AAV and healthy controls 
 Total No. of lymph.   
(cells x 10
9 
/l) 
 
P value 
CD3+ cells 
(% of lymph.) 
 
P value 
Healthy controls (N=30) 2.2 ± 0.4  70.9 ± 5.7  
AAV – all (N=69) 1.3 ± 0.7 <0.001 68.7 ± 12.9 n.s. 
AAV – active (N=43) 1.1 ± 0.6 <0.001 67.3 ± 12.1 n.s. 
AAV – remission (N=51) 1.5 ± 0.7 <0.001 69.8 ± 13.3 n.s. 
Data presented as mean ± standard deviation. P value represents the difference between patients with 
AAV and healthy controls. No. = number, lymph. = lymphocytes, n.s. = not significant. 
 
Table 4.2: Basic lymphocyte subpopulations in patients with AAV and healthy controls 
 CD4+  
(% of ly.)  
P 
value 
CD8+    
(% of ly.) 
P 
value 
CD19+   
(% of ly.) 
P 
value 
Healthy controls (N=30) 48.2 ± 7.5  22.0 ± 6.0  10.4 ± 3.2  
AAV – all (N=69) 40.4 ± 13.5 <0.001 29.0 ± 13.7 <0.05 9.6 ± 8.0 n.s. 
AAV – active (N=43) 42.1 ± 10.4 < 0.01 25.7 ± 12.1 n.s. 13.1 ± 8.4 n.s. 
AAV – remission (N=51) 39.1 ± 15.3 <0.001 31.6 ± 14.1 <0.001 6.9 ± 6.4 <0.01 
Data presented as mean ± standard deviation. P value represents the difference between patients with 
AAV and healthy controls. Ly. = lymphocytes, n.s. = not significant. 
 
However, the so-called immunoregulatory index (IRI, defined as 
CD3+CD4+/CD3+CD8+) was decreased in our AAV patients, i.e. we found lower 
percentage of CD4+ cells together with higher percentage of CD8+ in the AAV patients 
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(both active and, even more so, in remission, Table 4.2). In active AAV patients, the 
percentage of CD19+ cells (B lymphocytes) was higher than in HC, but this difference 
did not reach statistical significance. Significantly lower levels of B cells were observed 
in remission (p<0.01, Table 4.2); as shown below, even in patients in that 
immunosuppressive treatment had already been stopped.  
The number of natural killer (NK) cells (CD3–CD16,56+) in AAV did not differ 
from HC (Table 4.3). On the contrary, a significant decrease in naïve (CD4+CD45RA+) 
T cells was noted in all AAV patients when compared to HC, in particular in AAV 
patients in remission (p<0.001, Table 4.3). Patients with AAV in remission (and not 
active patients) had also higher numbers of activated HLA-DR+ CD3+ T cells than HC 
(p<0.01, Table 4.3). 
 
Table 4.3: NK cells, naïve T cells and activated T cells in patients with AAV and healthy 
controls 
 CD3–
CD16,56+ 
(% of ly.) 
 
P 
value 
CD4+ 
CD45RA+ 
(% of ly.) 
 
P 
value 
CD3+ 
HLA-DR+  
(% of ly.)  
 
P 
value 
Healthy controls (N=30) 15.3 ± 9.1  30.4 ± 11.7  4.6 ± 2.6  
AAV – all (N=69) 13.5 ± 9.7 n.s. 19.6 ± 8.9 <0.001 6.9 ± 6.8 <0.01 
AAV – active (N=43) 11.6 ± 8.0 n.s. 22.8 ± 9.4 <0.01 5.3 ± 3.4 n.s. 
AAV – remission (N=51) 15.0 ± 10.6 n.s. 17.2 ± 7.7 <0.001 8.1 ± 5.3 <0.01 
Data presented as mean ± standard deviation. P value represents the difference between patients with 
AAV and healthy controls. Ly. = lymphocytes, n.s. = not significant. 
 
 
 
 Furthermore, chemokine receptors expressed on CD4+ cells were examined. 
Even HC displayed low-level cell surface expression of inducible chemokine receptors, 
which may occur in response to any antigenic challenge. However, the expression of 
Th1-associated receptor CCR5 on CD4+ T lymphocytes was significantly increased in 
our patients when compared to HC (p<0.01, Table 4.4). In contrast to CCR5, neither 
active patients with AAV nor patients with remission differed from HC in the 
expression of another Th1-associated chemokine receptor, CXCR3 (Table 4.4).  
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Table 4.4: Th1-associated chemokine receptors on CD4+ T cells in AAV and healthy controls 
 CCR5+  
(% of CD4+ ly.)  
 
P value 
CXCR3+  
(% of CD4+ ly.) 
 
P value 
Healthy controls (N=30) 16.4 ± 8.4  37.1 ± 10.0  
AAV – all (N=69) 23.0 ± 11.6 <0.01 39.3 ± 16.6 n.s. 
AAV – active (N=43) 22.2 ± 14.4 <0.01 35.8 ± 10.4 n.s. 
AAV – remission (N=51) 23.7 ± 8.5 <0.01 42.3 ± 15.0 n.s. 
Data presented as mean ± standard deviation. P value represents the difference between patients with 
AAV and healthy controls. Ly. = lymphocytes, n.s. = not significant. 
 
 
On the other hand, the expression of Th2 associated chemoattractant receptor-
homologous molecule CRTH2 on CD4+ T lymphocytes and the expression of Th2 
associated surface marker CD30 was increased in our group of patients with AAV taken 
as a whole and in active patients in comparison to HC (p<0.05). In patients in remission, 
the expression of these molecules did not differ from HC (Table 4.5). 
 
Table 4.5: Expression of Th2-associated surface markers on lymphocytes in AAV and healthy 
controls 
 CRTH2+  
(% of  CD4 + ly.) 
 
P value 
CD30+  
(% of  ly.) 
 
P value 
Healthy controls (N=30) 6.5 ± 2.2  4.6 ± 2.8  
AAV – all (N=69) 10.6 ± 7.6 <0.05 7.4 ± 4.6 <0.05 
AAV – active (N=43) 12.1 ± 8.6 <0.05 8.0 ± 5.4 <0.05 
AAV – remission (N=51) 7.8 ± 2.8 n.s. 6.3 ± 2.1 n.s. 
Data presented as mean ± standard deviation. P value represents the difference between patients with 
AAV and healthy controls. Ly. = lymphocytes, n.s. = not significant. 
 
 
 Finally, the expression of CD28 and its ligands CD80 and CD86 on lymphocytes 
were assessed in this study. A significant increase in CD28–CD8+ subpopulation of 
lymphocytes (compared to HC) was observed in patients with AAV in remission 
(p<0.001, Table 4.6). This was accompanied by the increased expression of both ligands 
of CD28, i.e. CD80 and CD86, on CD19– lymphocytes (i.e. most probably T cells, 
p<0.01, Table 4.6). 
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Table 4.6: Expression of CD28 and its ligands CD80 and CD86 on lymphocytes in AAV and 
healthy controls 
 CD28–
CD8+ 
(% of  ly.) 
 
P 
value 
CD80+  
CD19– 
(% of ly.)  
 
P 
value 
CD86+ 
CD19– 
(% of ly.) 
 
P 
value 
Healthy controls (N=30) 13.3 ± 5.3  4.9 ± 3.1   6.1 ± 3.4  
AAV – all (N=69) 21.4 ± 15.3 <0.01 6.7 ± 4.0 <0.05 9.0 ± 4.2 <0.05 
AAV – active (N=43) 14.6 ± 11.1 n.s. 6.5 ± 4.6 n.s. 8.0 ± 3.7 n.s. 
AAV – remission (N=51) 26.5 ± 15.9 <0.001 6.9 ± 3.6 <0.01 10.9 ± 4.0 <0.01 
Data presented as mean ± standard deviation. P value represents the difference between patients with 
AAV and healthy controls. Ly. = lymphocytes, n.s. = not significant. 
 
4.1.2 Intracellular cytokines  
 
In this study, the intracellular production of IFN , the hallmark cytokine of Th1 
cells, did not differ between active patients with AAV and HC (Table 4.7). On the 
contrary, patients in remission displayed significantly higher production of IFN  than 
HC (p<0.01, Table 4.7).  
The intracellular production of IL-4 (associated with Th2 cells and Th2 type of 
immune response) was low in both patients with AAV and HC in this study. No 
significant difference in the IL-4 production was observed (Table 4.7).  
 
Table 4.7: Intracellular cytokine (IFN  and IL-4) production in CD3+ T lymphocytes in 
patients with AAV and healthy controls 
 IFN
1
  P value IL-4
1
 P value 
Healthy controls (N=24) 29.8 ± 9.8  3.6 ± 3.4  
AAV – all (N=69) 34.8 ± 16.5 n.s. 4.5 ± 4.0 n.s. 
AAV – active (N=43) 28.3 ± 13.0 n.s. 4.6 ± 3.4 n.s. 
AAV – remission (N=51) 41.8 ± 18.9 <0.01 4.5 ± 4.9 n.s. 
Data presented as mean ± standard deviation. P value represents the difference between patients with 
AAV and healthy controls. 
1
In % of CD3+ cells; n.s. = not significant. 
 
The TNF  production in AAV patients was also similar to HC (Table 4.8) in 
this study. Furthermore, we did not find any significant difference in the IL-2 
production between patients with AAV at any stage of the disease and HC (Table 4.8). 
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Table 4.8: Intracellular cytokine (TNF  and IL-2) production in CD3+ T lymphocytes in 
patients with AAV and healthy controls 
 TNF
1
  P value IL-2
1
 P value 
Healthy controls (N=24) 45.4 ± 19.4  31.1 ± 11.8  
AAV – all (N=69) 49.0 ± 24.0 n.s. 34.5 ± 18.9 n.s. 
AAV – active (N=43) 45.2 ± 20.0 n.s. 35.9 ± 17.0 n.s. 
AAV – remission (N=51) 52.0 ± 20.4 n.s. 31.9 ± 17.2 n.s. 
Data presented as mean ± standard deviation. P value represents the difference between patients with 
AAV and healthy controls. 
1
In % of CD3+ cells; n.s. = not significant. 
 
Regarding the intracellular cytokine production in monocytes, no significant 
difference in the IL-10 production between AAV patients and HC was noted. As for the 
IL-12, significantly higher IL-12 production was observed in patients with AAV than in 
HC, both in active patients and in patients in remission (p<0.01 and 0.05, respectively, 
Table 4.9).  
 
Table 4.9: Intracellular cytokine (IL-10 and IL-12) production in monocytes in patients with 
AAV and healthy controls 
 IL-10
1
  P value IL-12
1
 P value 
Healthy controls (N=24) 14.3 ± 9.8  10.2 ± 9.8  
AAV – all (N=69) 14.4 ± 10.3 n.s. 17.9 ± 13.2 <0.05 
AAV – active (N=43) 17.3 ± 14.2 n.s. 20.8 ± 14.2 <0.01 
AAV – remission (N=51) 12.2 ± 6.4 n.s. 16.5 ± 13.0 <0.05 
Data presented as mean ± standard deviation. P value represents the difference between patients with 
AAV and healthy controls. 
1
In % of monocytes; n.s. = not significant. 
 
4.1.3 Results of correlation analysis 
 
In this study, no significant difference in the measured parameters between 
genders was found. In the correlation analysis, we prospected for a possible correlation 
between the acquired laboratory data and age, glomerular filtration rate (GFR), ANCA 
levels and BVAS. However, no correlation between age and laboratory parameters was 
observed, nor did GFR significantly correlate with any of the surface markers or 
intracellular cytokines (Table 4.10).  
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Results of the correlations between ANCA levels or BVAS and measured 
variables are summarized in Table 4.10. ANCA levels significantly positively correlated 
with the percentage of IL-10 and IL-12 producing cells, and with the percentage of 
CD19 cells. On the other hand, a significant negative correlation between ANCA levels 
and CD28–CD8+ cells was observed. Furthermore, BVAS but not ANCA levels 
significantly positively correlated with the numbers of CRTH2+, and CD30+ cells. A 
positive correlation of the number of IL-10 producing cells and BVAS was also found. 
 
Table 4.10: Correlation matrix 
 Age GFR
5
  ANCA BVAS 
CD4+
1
 0 0 0.1, n.s. 0.1, n.s. 
CD8+
1
 0 0 -0.1, n.s. -0.1, n.s. 
CD19+
1
 0 0 0.4** 0.2, n.s. 
CD3+HLA-DR+
1
 0.3, n.s. -0.1, n.s. 0 0.2, n.s. 
CD4+45RA+
1
 -0.2, n.s. 0.1, n.s. 0.1, n.s. 0.1, n.s. 
CD28–CD8+1 0.3, n.s. 0.1, n.s. -0.3* -0.2, n.s. 
CD30+
1
 0.2, n.s. 0.2, n.s. 0.3, n.s. 0.8** 
CCR5+
2
 0.2, n.s. 0 -0.2, n.s. - 0.1, , n.s. 
CXCR3+
2
 0.2, n.s. 0 -0.2, n.s. - 0.1, n.s. 
CRTH2+
2
 0.1, n.s. 0.1, n.s. 0.2, n.s. 0.6* 
IFNγ3 0.3, n.s. 0.2, n.s. -0.1, n.s. -0.1, n.s. 
IL-4
3
 0 0 0.2, n.s. 0.1, n.s. 
TNF
3
 0.3, n.s. 0.2, n.s. -0.1, n.s. 0 
IL-2
3
 0.1, n.s. 0.1, n.s. 0.1, n.s. 0 
IL-10
4
 0.1, n.s. 0 0.4*** 0.3* 
IL-12
4
 0.1, n.s. 0 0.3** 0.2, n.s. 
Expressed as the correlation coefficient ; 0 =  <0.1;  
* = p < 0.05, ** =  p < 0.01, *** = p < 0.001, n.s. = not significant 
1
In % of lymphocytes, 
2 
in % of CD4+ lymphocytes,  
3 
in % of CD3+ cells, 
4
in % of monocytes  
5
 GFR = glomerular filtration rate, calculated with the help of the MDRD formula [159]. 
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4.1.4 Comparison of active patients and patients in remission 
 
The numeric results of surface molecule and intracellular cytokine examination 
in both active patients with AAV and patients with AAV in remission have been shown 
above (Tables 4.1-4.9). In this chapter, results of the comparison of active patients and 
patients in remission have been summarized.  
Several significant differences in the basic lymphocytes subpopulations and the 
expression of surface molecules between active patients and patients in remission were 
noted (Fig. 4.1 and 4.2). Patients with AAV in remission had significantly higher 
percentage of CD8+ cells when compared to active AAV (p<0.05, Fig. 4.1). On the 
contrary, CD19+ cell count in remission was significantly lower than in active patients 
(p<0.001, Fig. 4.1). A decrease in CD4+45RA+ naïve T cells was also observed in 
remission (Fig. 4.1).  
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Fig. 4.1: Significant differences in lymphocyte subpopulations between active patients with 
AAV and patients in remission. Data presented as mean, error bars represent standard deviation. 
 
On the other hand, the number of activated (HLA-DR+) T cells and also of 
CXCR3+ CD4+ cells was significantly higher in remission than in active disease (Fig. 
4.2). Finally, patients in remission had a significant expansion of CD28– subpopulation 
of CD8+ cells (Fig. 4.2). No other significant difference in the surface molecule 
expression between active patients and patients in remission was found in this study.  
 
p   0.05 
 
p   0.001 
 
p   0.01 
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Fig. 4.2: Significant differences in surface molecule expression between active patients with 
AAV and patients in remission. Data presented as mean, error bars represent standard deviation. 
 
 As for the intracellular cytokine production, active patients with AAV had 
significantly lower production of IFN  than patients in remission (p<0.01, Fig. 4.3). On 
the contrary, the production of IL-10 was significantly higher in active patients than in 
remission (p<0.05, Fig. 4.3). The difference between active patients and patients in 
remission in the intracellular production of other determined cytokines, i.e. IL-2, IL-4, 
TNF  and IL-12, was not statistically significant. 
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Fig. 4.3: Significant differences in the intracellular cytokine production between active patients 
with AAV and patients in remission. Data presented as mean, error bars represent standard 
deviation. 
 
 In the subsequent subgroup analysis, results of newly active patients were 
compared to patients with relapse. In the surface molecules expression, the only 
significant difference between these two subgroups of active patients was a lower 
p   0.05 
 
p   0.05 
 p   0.01 
 
p   0.01 
 
p   0.05 
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number of CD19+ cells (B lymphocytes) in patients with relapse; the other results did 
not significantly differ. 
Nevertheless, more intriguing results were obtained in the comparison of the 
intracellular cytokine production. The production of IL-10 was significantly higher in 
newly diagnosed patients than in patients with relapse but did not significantly differ 
from healthy controls (Fig. 4.4.). Furthermore, newly diagnosed patients had increased 
IL-12 production when compared to patients with relapse, and, in this case, also to 
healthy controls (Fig. 4.4). No other significant difference in the intracellular cytokine 
production between newly active patients and patients with relapse was found. 
 
 
 
 
Fig. 4.4: Intracellular cytokine production of IL-10 and IL-12 in monocytes. Box plots indicate 
5-95% range (error bars), 25-75% range (boxes), median value (horizontal lines) and mean (+). 
* p<0.05, *** p<0.001. NA = newly active patients with ANCA-associated vasculitis (N=20); 
REL = active patients with ANCA-associated vasculitis with relapse (N=14); HC = healthy 
controls (N=24). 
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4.1.5 Comparison of PR3-ANCA and MPO-ANCA-associated disease 
  
Table 4.11: Comparison of surface molecule expression and intracellular cytokine production 
between PR3-ANCA-associated and MPO-ANCA-associated disease 
 PR3-
ANCA-
active 
(N=32) 
MPO-
ANCA-
active  
(N=11) 
 
P 
value 
PR3-
ANCA-
remission 
(N=28) 
MPO-
ANCA-
remission 
(N=23) 
 
P 
value 
CD4+
1
 
42.3 ± 9.7 41.6 ± 12.3 n.s. 41.4 ± 16.2  36.2 ± 13.6 n.s. 
CD8+
1
 
27.7 ± 12.9 19.5 ± 6.3 n.s. 31.3 ± 12.5 31.9 ± 15.9 n.s. 
CD19+
1
 
12.4 ± 8.8 15.0 ± 6.6 n.s. 7.3 ± 7.4 6.3 ± 4.7 n.s. 
CD3+HLADR+
1
 
5.1 ± 3.6 5.8 ± 2.5 n.s. 6.7 ± 5.0 9.8 ± 4.6 n.s. 
CD4+45RA+
1
 
22.0 ± 9.3 25.3 ± 9.1 n.s. 18.3 ± 8.0 15.8 ± 7.1 n.s. 
CD3–CD16,56+1 
9.9 ± 5.7 16.7 ± 11.1 <0.05 13.6 ± 8.0 16.7 ± 12.8 n.s. 
CD28–CD8+1 
14.0 ± 11.3 16.6 ± 10.1 n.s. 22.7 ± 15.5 31.5 ± 15.0 n.s. 
CD30+
1
 
7.1 ± 5.6 9.8 ± 4.4 n.s. 6.6 ± 2.3 5.4 ± 1.4 n.s. 
CCR5+
2
 
20.6 ± 8.4 25.7 ± 22.0 n.s. 22.6 ± 8.4 24.9 ± 8.5 n.s. 
CXCR3+
2
 
35.3 ± 11.2 37.0 ± 7.8 n.s. 38.3 ± 7.7 47.1 ± 19.6 n.s. 
CRTH2+
2
 
15.0 ± 9.8 9.8 ± 3.6 n.s. 8.3 ± 2.0 7.3 ± 3.3 n.s. 
IFNγ3 
27.0 ± 11.9 31.5 ± 15.4 n.s. 39.2 ± 18.6 43.2 ± 16.8 n.s. 
IL-4
3
 
4.3 ± 3.2 4.7 ± 3.4 n.s. 5.6 ± 5.7 3.1 ± 2.2 n.s. 
TNF
3
 
42.5 ± 17.1 49.1 ± 23.5 n.s. 51.9 ± 19.0 54.1 ± 21.9 n.s. 
IL-2
3
 
35.4 ± 16.4 36.4 ± 16.8 n.s. 34.1 ± 17.5 31.5 ± 15.7 n.s. 
IL-10
4
 
15.1 ± 9.4 20.8 ± 12.9 n.s. 13.5 ± 6.9 11.6 ± 6.1 n.s. 
IL-12
4
 
18.8 ± 15.1 26.8 ± 12.6 n.s. 15.3 ± 8.7 18.0 ± 15.5 n.s. 
Data presented as mean ± standard deviation. P value represents the difference between patients with 
PR3-ANCA-associated disease and MPO-ANCA associated disease (for active patients and patients in 
remission, respectively). n.s. = not significant.  
1
In % of lymphocytes, 
2 
in % of CD4+ lymphocytes,  
3 
in 
% of CD3+ cells, 
4
in % of monocytes  
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Basic clinical and demographic characteristics of patients with PR3-ANCA- and 
MPO-ANCA-associated disease have been shown above (Chapter 3). Patients with 
MPO-ANCA-associated disease were significantly older than patients with PR3-
ANCA-associated disease (p<0.05). No other significant difference in the basic 
parameters was observed. 
Few differences were also found in the measured laboratory parameters. Patients 
with active PR3-ANCA-associated disease had significantly lower numbers of 
CD3 CD16,56+ cells (NK cells) than patients with active MPO-ANCA-associated 
disease (p<0.05, Table 4.11). The difference in all other parameters did not reach 
statistical significance (Table 4.11). Similarly, no significant difference between 
patients with PR3-ANCA and MPO-ANCA-associated disease in remission was found 
even though a tendency to differ was indicated in some parameters (e.g. in CXCR3+ or 
CD28 CD8+ cells). 
 
 
4.1.6 Comparison of patients with different therapies 
 
To elucidate the possible influence of immunosuppressive therapy on the results, 
a total of 10 yet untreated patients with active disease were examined in this study. 
Results of the comparison of untreated active patients with AAV and active patients 
with AAV on immunosuppressive therapy are shown in Table 4.12. 
In comparison with active patients on immunosuppressive therapy, the active 
untreated patients had significantly lower numbers of CD8+ cells (p<0.05). They also 
had significantly lower percentage of CD80+ cells within the CD19+ subpopulation of 
lymphocytes (p<0.01, Table 4.12). No other significant differences between treated and 
untreated active patients were found. 
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Table 4.12: Comparison of surface molecule expression and intracellular cytokine production 
between active untreated patients with AAV and active patients with AAV on therapy 
 Active 
untreated (N=10) 
Active on 
therapy  (N=33) 
 
P value 
CD4+
1
 
40.2 ± 11.1 42.7 ± 10.1 n.s. 
CD8+
1
 
19.8 ± 7.6 27.3 ± 12.6 <0.05 
CD19+
1
 
15.6 ± 5.3 12.3 ± 8.9 n.s. 
CD3+HLA-DR+
1
 
5.3 ± 4.3 5.3 ± 3.1 n.s. 
CD4+45RA+
1
 
21.6 ± 8.7 23.0 ± 9.5 n.s. 
CD3–CD16,56+1 
15.2 ± 8.5 10.6 ± 7.5 n.s. 
CD28–CD8+1 
14.6 ± 11.7 14.6 ± 10.9 n.s. 
CCR5+
2
 
18.1 ± 6.1 23.4 ± 15.8 n.s. 
CXCR3+
2
 
38.9 ± 8.5 34.8 ± 10.7 n.s. 
CD80+
3
 
18.6 ± 9.2 34.1 ± 20.3 <0.01 
CD86+
3
 
21.1 ± 10.9 34.1 ± 17.9 n.s. 
IFNγ4 
28.8 ± 14.1 28.1 ± 12.8 n.s. 
IL-4
4
 
5.9 ± 4.0 3.8 ± 2.7 n.s. 
TNF
4
 
41.7 ± 22.2 46.5 ± 19.5 n.s. 
IL-2
4
 
29.9 ± 16.8 37.5 ± 16.0 n.s. 
IL-10
5
 
18.3 ± 14.5 16.8 ± 14.4 n.s. 
IL-12
5
 
20.4 ± 15.6 20.9 ± 14.0 n.s. 
Data presented as mean ± standard deviation. P value represents the difference between active untreated 
patients with AAV and active patients with AAV on therapy. n.s. = not significant.  
1
In % of lymphocytes, 
2 
in % of CD4+ lymphocytes,  
3 
in % of CD19+ lymphocytes,
  4 
in % of CD3+ cells, 
5
in % of monocytes.  
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Table 4.13: Comparison of surface molecule expression and intracellular cytokine production 
between patients with AAV in remission on therapy and patients in remission without therapy 
 Remission on 
therapy (N=35) 
Remission 
untreated  (N=16) 
 
P value 
CD4+
1
 
40.3 ± 17.0 36.4 ± 10.3 n.s. 
CD8+
1
 
32.7 ± 13.6 29.2 ± 14.8 n.s. 
CD19+
1
 
6.6 ± 6.7 7.4 ± 5.5 n.s. 
CD3+HLA-DR+
1
 
8.7 ± 9.2 6.8 ± 5.4 n.s. 
CD4+45RA+
1
 
16.5 ± 7.7 18.5 ± 7.6 n.s. 
CD3–CD16,56+1 
12.2 ± 9.5 21.3 ± 10.2 <0.01 
CD28–CD8+1 
25.5 ± 15.6 27.1 ± 15.3 n.s. 
CD80+CD19-
1
 
7.5 ± 3.4 5.2 ± 2.5 <0.05 
CCR5+
2
 
24.6 ± 8.2 21.0 ± 8.8 n.s. 
CXCR3+
2
 
43.6 ± 15.2 38.5 ± 13.8 n.s. 
CD80+
3
 
38.5 ± 17.6 17.1 ± 11.0 <0.001 
IFNγ4 
40.8 ± 17.8 42.1 ± 18.1 n.s. 
IL-4
4
 
5.0 ± 4.9 3.0 ± 2.1 n.s. 
TNF
4
 
49.2 ± 20.0 55.6 ± 19.1 n.s. 
IL-2
4
 
27.6 ± 16.2 40.4 ± 15.8 =0.05 
IL-10
5
 
11.7 ± 7.1 12.7 ± 5.4 n.s. 
IL-12
5
 
18.0 ± 14.0 13.2 ± 6.4 n.s. 
Data presented as mean ± standard deviation. P value represents the difference between patients with 
AAV in remission on therapy and patients in remission without therapy. n.s. = not significant.  
1 
 In % of lymphocytes, 
2 
in % of CD4+ lymphocytes,  
3 
in % of CD19+ lymphocytes,
  4 
in % of CD3+ 
cells, 
5
in % of monocytes. 
 
 
When patients in remission on maintenance immunosuppressive therapy were 
compared to patients in remission in whom the immunosuppressive therapy had been 
stopped before the examination, the patients on therapy had significantly lower number 
of NK cells (p<0.01, Table 4.13). Moreover, higher expression of CD80 both on CD19– 
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lymphocytes (p<0.05) and also within the CD19+ subpopulation (p<0.001) was found 
in patients on immunosuppressive therapy. The IL-2 production was lower in patients in 
remission on therapy than in those without therapy, even though this difference reached 
borderline significance only (p=0.05). The remaining results of the surface molecule 
expression and the intracellular cytokine production did not significantly differ between 
these two subgroups of patients with AAV. 
We also separately analysed and compared patients in remission treated by 
cyclophosphamide (CYC) with patients in remission treated by azathioprine (AZA) or 
mycophenolate-mofetil (MMF). The subgroups of patients were overall small and thus 
difficult to assess statistically. However, an increased number of CD3+HLA-DR+ cells 
was noted in the CYC subgroup of remission patients compared to the AZA/MMF 
subgroup. No other significant difference between patients on CYC and patients on 
AZA/MMF was found (Table 4.14).  
 
Table 4.14: Comparison of surface molecule expression and intracellular cytokine production 
between patients in remission treated with CYC and patients in remission treated with AZA or 
MMF 
 Remission on 
CYC (N=7) 
Remission on 
AZA/MMF  (N=18) 
 
P value 
CD4+
1
 
44.8 ± 13.2  40.1 ± 17.8 n.s. 
CD8+
1
 
32.4 ± 11.7 32.8 ± 11.7 n.s. 
CD19+
1
 
5.0 ± 3.2 6.8 ± 7.7 n.s. 
CD3+HLA-DR+
1
 
15.4 ± 16.0 5.6 ± 4.1 <0.05 
IFNγ2 
33.4 ± 11.5 43.1 ± 20.1 n.s. 
IL-4
2
 
5.8 ± 3.6 5.0 ± 6.3 n.s. 
TNF
2
 
53.6 ± 16.9 48.2 ± 23.5 n.s. 
IL-2
2
 
34.3 ± 15.5 26.5 ± 17.4 n.s. 
IL-10
3
 
9.8 ± 5.5 12.8 ± 7.0 n.s. 
IL-12
3
 
12.9 ± 9.6 18.9 ± 9.1 n.s. 
Data presented as mean ± standard deviation. P value represents the difference between patients with 
AAV in remission on CYC and patients in remission on AZA/MMF. CYC=cyclophosphamide, 
AZA=azathioprine, MMF=mycophenolate-mofetil, n.s. = not significant.  
1 
 In % of lymphocytes,
  2 
in % of CD3+ cells, 
3
in % of monocytes.  
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4.2 Long-term follow-up  
 
Special emphasis in this study was placed on discerning any lymphocyte 
subpopulations or cytokine patterns potentially associated with the prognosis. As 
mentioned above, 8 patients died during the follow-up. Nevertheless, no relationship 
between the measured parameters and subsequent death was found.  
On the contrary, intriguing results were obtained when patients in remission who 
subsequently relapsed during the follow-up (N=19) were compared to those without 
relapse (N=32). Clinical characteristics of these two subgroups of patients were shown 
above (see Chapter 3). There was no significant difference in age, gender, ANCA 
specificity or serum creatinine levels between these two subgroups. Patients with and 
without relapse also did not significantly differ in the proportion of the basic 
lymphocyte subpopulations and surface molecule expression.  
In contrast to surface molecules, significant differences were noted in the 
intracellular cytokine production, namely in the IL-10 production. The IL-10 production 
in remission was significantly lower in the patients who subsequently relapsed than in 
those who did not (p<0.01, Fig. 4.5); it was even significantly lower than in HC 
(p<0.05, Figure 4.5). However, no correlation between the length of remission and IL-
10 production was observed. There was also no correlation between the IL-10 
production and the time to relapse.  
Patients in remission without relapse during the follow-up tended to display 
higher IL-12 levels than those with relapse but the difference between these two 
subgroups was not statistically significant (Figure 4.5). Nevertheless, as shown in Fig. 
4.5, the IL-12 production was higher in patients in remission without subsequent relapse 
than in HC.  
The production of IFN , TNF , IL-2 and IL-4 did not significantly differ 
between patients in remission with subsequent relapse and those without relapse. 
 
  
57 
 
Fig. 4.5: Intracellular cytokine production in patients with AAV and healthy controls. Box plots 
indicate 5-95% range (error bars), 25-75% range (boxes), median value (horizontal lines) and 
mean (+). * p<0.05, ** p<0.01. W.REL = patients with ANCA-associated vasculitis who 
relapsed during follow-up (N=19); WO. REL = patients with ANCA-associated vasculitis who 
did not develop relapse during follow-up (N=32); HC = healthy controls (N=24). 
 
4.3 Patients treated with rituximab – preliminary results 
 
Long-term B cell depletion lasting 9-30 months (median 13.5 months) after 
rituximab (RTX) administration was observed in all treated patients with AAV (see Fig. 
4.6 for an example of flow cytometric results in a RTX treated patient). Whilst in 2 
newly diagnosed patients with MPA, and RLV respectively, complete remission (CR) 
was achieved, in 4 patients with refractory AAV (WG in all cases) RTX administration 
led to partial remission/stabilization (PR) of the disease in 2 patients and did not have 
any favourable effect in 2 patients with predominant pulmonary granulomatous 
involvement.  
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Fig. 4.6: Example of flow cytometric results (patient with normal B cell subpopulation on the 
left, patient treated with RTX with complete B cell depletion on the right) 
 
The intracellular cytokine production varied deeply among the RTX treated 
patients. However, interestingly, an increase in IL-10 production 3 months after RTX 
administration was noted in 4 patients who achieved CR or PR (p<0.05) but not in the 
other two patients without favourable effect of RTX (Fig. 4.7).  
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Fig. 4.7: Intracellular production of IL-10 in AAV patients before and 3 months after RTX 
administration. 
 
Furthermore, complete B cell depletion induced by RTX was accompanied by 
significant changes in the lymphocyte subpopulations and altered also T cell phenotype 
in all patients. One of the prominent findings was a significant increase in CD3+HLA-
DR+ cells observed early after RTX administration in all patients. The development of 
the number of CD19+ cells, number of CD3+HLA-DR+ cells, and also ANCA and IgG 
levels after RTX administration is illustrated in Fig. 4.8 in the example of a patient with 
RLV who responded well to the therapy and achieved CR.  
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Fig. 4.8: Development of IgG and ANCA levels, and the percentage of CD3+HLA-DR+ cells 
and CD19+ cells (in the top-down order) after rituximab administration in a patient with AAV. 
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5. DISCUSSION 
 
 
 ANCA-associated vasculitis is an autoimmune inflammatory disease in which 
tissue injury most probably results from the interaction of ANCA, neutrophils, and 
endothelial cells, with presumed role of impaired T cell functions throughout the 
pathogenic process. While most authors focused on the role of ANCA in the 
pathogenesis of AAV, the cellular immunity in AAV has only recently attracted 
attention. This study therefore aimed to assess various cellular immunity parameters 
(i.e. lymphocyte subpopulations, surface molecule expression, and intracellular cytokine 
production) in patients with AAV at different stages of the disease, with different 
treatment modalities, and with respect to the long-term prognosis of the patients.  
 Since the patients were recruited from a Nephrology Department, renal 
involvement was present in all but one of our patients. Given the low incidence and 
prevalence of the disease, 69 patients with AAV included into our study represent a 
relatively large and homogenous cohort of patients with generalized vasculitis and 
major organ (renal) involvement. We were also able to examine a total of 26 patients 
(including 10 active patients) without any immunosuppressive treatment, which has 
been a logistic problem in many previous studies [94, 97, 115]. Moreover, the 
demographic and clinical data of our patients as presented in Chapter 3 bear striking 
resemblance to the data obtained from a long-term follow-up of all consecutive patients 
with AAV performed at our centre previously [160]. For instance, in agreement with the 
long-term follow-up (and also other studies), patients with MPO-ANCA-associated 
disease in this study were significantly older than patients with PR3-ANCA-associated 
disease. Male gender also slightly predominated in both studies. Thus, the cohort of our 
patients likely forms a representative sample of AAV patients with renal involvement.  
 As discussed in detail below, we found distinct abnormalities in the numbers 
and phenotype of peripheral blood lymphocytes as well as in the intracellular cytokine 
production in patients with generalized AAV. Despite somewhat different methodology, 
our findings strengthen and further extend results of a number of earlier studies [94-98, 
112-115, 118-119, 121, 127-128, 161-164]. Nevertheless, it is difficult to make direct 
comparisons with other studies, in particular in the case of the cytokine production 
assessment. While most authors measured cytokine levels with enzyme immunoassays 
either directly in blood samples [94, 118, 161, 162] or after stimulation in culture 
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supernatants [86, 121], and others measured cytokine mRNA with reverse transcriptase-
polymerase chain reaction [112, 113, 118], the flow cytometric analysis of intracellular 
cytokine production similar to our study was less frequent [97, 119] and not related to 
the long-term prognosis. The advantage of this method is that the intracellular cytokine 
production after stimulation reflects the ability of blood cells to produce the respective 
cytokine after activation, and not only cytokine levels themselves. In vivo, this 
activation might be mediated by various infectious stimuli (in WG e.g. by nasal carriage 
of Staphylococcus aureus as suggested earlier [117]). Another advantage of flow 
cytometric analysis is also the possibility to precisely define the cytokine-producing 
population. On the other hand, we are aware that the need of artificial stimulation is a 
possible limitation of flow cytometric analyses as the spectrum of activated cytokine 
production might differ from activation induced in vivo by antigen-presenting cells.  
 Compatibly with findings of others [97, 163, 164], patients with AAV in this 
study had significantly lower total number of lymphocytes, diminished  proportion of  
CD4+ cells and enlarged proportion of CD8+ cells when compared to healthy 
individuals. Notably, lower numbers of lymphocytes and CD4+ cells were observed in 
all subgroups of AAV patients, including the untreated active ones. Therefore, 
immunosuppressive therapeutic regimens themselves cannot be blamed for these 
findings. On the contrary, patients in remission on cyclophosphamide had relatively 
highest CD4+ cell counts among AAV patients. We presume that the decrease in the 
total number of circulating lymphocytes might reflect the initial pathogenic vasculitic 
process with lymphocyte pooling in peripheral tissues. The inflammatory lesions and 
granulomas in AAV are known to contain significant numbers of CD4+ T cells along 
with macrophages and neutrophils [81, 128, 131], which might at least partly explain 
low numbers of CD4+ cells in peripheral blood in AAV patients.  
 In line with this, it is necessary to have a closer look at the population of CD8+ 
cells. The significant expansion of CD8+ cells in this study was observed in remission 
phase of the disease but not in active patients, in particular not in the untreated ones. 
The influence of administered immunosuppressive therapy (i.e. mostly corticosteroids 
and pulsed intravenous cyclophosphamide) on the numbers of CD8+ cells seems 
therefore likely. Indeed, the increase in the percentage of CD8+ cells and the decline of 
the IRI after cyclophosphamide administration have been previously reported in patients 
with multiple sclerosis [165] or systemic lupus erythematodes [166]. 
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 However, we show that increased CD8 numbers prevail long after 
cyclophosphamide (and any other immunosuppressive) treatment have been stopped 
and no difference in CD8+ cell counts was found between patients in remission on 
cyclophosphamide and those on maintenance immunosuppressive therapy (i.e. 
azathioprine or mycophenolate-mofetil). Therefore, other factors that account for the 
expansion of CD8+ cell population in AAV are likely to be identified.  
 Interestingly, Giscombe et al. [126] described upregulated expression of co-
stimulatory molecules of tumour necrosis factor receptor (TNFR) superfamily on 
expanded CD8+ T cells but not on CD4+ cells in WG. Thus, TNFR expression on 
CD8+ cells might augment clonal expansion and differentiation, and sustain longevity 
of cytotoxic T cell response [132]. 
 Furthermore, Iking-Konert et al. [164] reported on the presence of a small 
population of CD8+CD28+ cells expressing activation marker CD11b during active 
vasculitis. This population is considered a transient ―intermediate‖ phenotype in the 
process of CD8+ activation, giving rise to a more persistent phenotype CD8+CD28–
CD11b+ found in remission and under immunosuppressive therapy. Activated CD8+ 
cells may therefore play an important role in the pathogenesis of AAV, either by 
inducing differentiation of polymorphonuclear neutrophils [164] or by direct 
contribution to the damage of vascular endothelium, as suggested by others [163].  
 In accordance with these findings, a significant increase in CD28–CD8+ cells 
was noted in patients in remission in our study as well as in previous studies [126, 127]. 
Similarly as others [164], we also observed that low IRI (CD4:CD8 ratio) correlated 
with a high percentage of CD28–CD8+ cells (Fig. 5.1). Iking-Konert et al. [164] 
reported that a low IRI was generally associated with a long lasting, severe disease and 
renal involvement. As renal involvement was present in nearly all our patients, we were 
only able to prospect for a possible relationship between disease duration and low IRI. 
No such relationship was, however, found in this study as well as some previous studies 
[127]. 
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Fig. 5.1: Low immunoregulatory index (IRI) correlates with a high percentage of CD28–CD8+ 
cells. 
 
 In contrast to observations of others [127], we did find a significant difference 
in the numbers of CD28–CD8+ cells between active patients and patients in remission 
in this study. In our experience, CD28–CD8+ cells were lower in active disease than in 
remission; they even negatively correlated with ANCA levels. Notably, no difference 
between newly diagnosed patients and patients with relapse was found (14.8 11.0, and 
14.4 10.9 respectively). Taken the findings of Iking-Konert et al. [164] into account, 
the explanation might be that in active disease a population of CD8+CD28+ cells 
prevails and the loss of CD28 expression occurs later in the period of active disease and 
persists in remission. In that case the timing of blood sample collection during active 
disease would be important; in our study, most of the active patients were examined 
soon after the disease activity appeared. 
 Molecules CD80 and CD86 are CD28 ligands. Both are normally expressed on 
antigen-presenting cells and their interaction with CD28 on T cells provides a co-
stimulatory signal required for T cell activation. In this study, the expression of neither 
CD80 nor CD86 on CD19+ (B) cells in AAV differed from healthy controls (data not 
shown). Nevertheless, the expression of CD80 within the CD19+ population was 
significantly lower in untreated active patients than in active patients on 
immunosuppression, and decreased after the withdrawal of immunosuppressive therapy 
in remission. Thus, while B cell numbers generally decrease on therapy, the expression 
of CD80 per B cell increases. At this point, it is important to highlight that this finding 
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would not be noted if only the total numbers of CD80 expressing B cells were 
considered. Instead of this, the proportion of CD19+ cells expressing CD80 was 
calculated in this study (as the percentage of CD80+CD19+ cells divided by the 
percentage of CD19+ cells, multiplied by 100). In our opinion, such a calculation helps 
to prevent misinterpretation of the results, e.g. in the case of low CD19+ cell numbers 
under immunosuppression, and was therefore used repeatedly. 
 Intriguingly, increased expression of both CD80 and CD86 on CD19– cells was 
observed in AAV patients in remission when compared to healthy controls. At the time 
of the blood sample examination, FACS with three-colour imaging only was available 
at our centre. However, as the up-regulation of CD80 and CD86 on T cells in patients 
with AAV had been reported before [127], we supposed that the CD19 negative 
population represented T cells. Later on, with six colours available, we were, indeed, 
able to verify the unusual presence of CD80 and CD86 on both CD4+ and CD8+ cells 
in AAV, as portrayed in Fig. 5.2 
 
.  
Fig. 5.2: Example of unusual expression of CD80 on CD4+ cells (on the left) and expression of 
CD86 on CD8+ cells (on the right). 
 
 Both the expansion of CD28– cells and the up-regulation of CD28 ligands on T 
cells seem to go hand in hand with the ongoing inflammation in AAV patients. The loss 
of CD28 expression on T cells is considered a consistent biological indicator of aging in 
the human immune system. It has been noted that in immunopathological processes, 
including AAV, CD28– T cells likely represent prematurely senescent lymphocytes due 
to persistent immune activation [167]. Regarding the increased expression of CD80 and 
CD86 on T cells, a self-co-stimulation of these cells is, theoretically, conceivable [127]. 
Thus, the increased expression of co-stimulatory molecules on T cells may lead to 
peripheral blood T cell stimulation and contribute to the persistent T cell activation in 
AAV.  
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 As mentioned in Chapter 2, most authors agree that in contrast to soluble T cell 
markers and to activation markers on B lymphocytes, activation markers on T cells (e.g. 
CD25 and HLA-DR) in AAV seem not to correlate with disease activity; they are up-
regulated even in remission and despite treatment [96, 98]. The hypothesis of persistent 
immune system activation in remission of AAV has been supported by several results of 
our study. On the whole, these findings indicate the possible importance of ongoing 
immunosuppressive treatment in patients with AAV in remission.  
 Marinaki et al. [98] defined persistent T cell activation (PTA) in AAV as either 
of two activation phenotypes, i.e. a low percentage of CD4+CD45RO– (naïve) T cells 
or a high percentage of CD25 in the naïve CD4+ population. In agreement with the 
findings of Marinaki et al., a significant decrease in CD4+CD45RA+ naïve T cells was 
observed in all subgroups of patients with AAV in our study, including the subgroup of 
yet untreated active patients and also patients with sustained remission. Notably, the 
decrease in the CD4+CD45RA+ cell population was even more evident in patients in 
remission. 
 Correspondingly, the numbers of activated HLA-DR positive CD3+ (T) cells 
were significantly higher in patients in remission than in healthy controls and active 
patients in our study. However, in contrast to previous studies [96, 121], significantly 
increased numbers of circulating HLA-DR+ T cells were not found in our active 
patients with AAV. Accordingly, higher IFN  production than in healthy individuals 
was observed in our patients with AAV in remission but not in active disease. The 
production of IFN  in remission of AAV might be sustained by expanded CD28– 
population of CD4+ T effector memory cells as reported in previous studies [128]. 
 Taken together, our data give enough evidence for the presence of activated T 
cells in remission of AAV. The explanation for relatively low markers of T cells 
activation found in active disease in this study is not entirely clear. Marinaki et al. [98] 
have previously reported on the strong variation of HLA-DR+ cell numbers during 
longitudinal follow-up. CD25+ cells of non-regulatory phenotype, which were not 
assessed in our study, were therefore considered a more appropriate marker of persistent 
T cell activation than HLA-DR by those authors [98]. On the other hand, HLA-DR and 
CD25 appear on T cells at different stages of activation. HLA-DR appears later than 
CD25 and persists for a longer period [126]. Thus, the above-mentioned timing of blood 
sample examination may have contributed to lower numbers of HLA-DR+ cells in 
active disease in this study.  
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 In theory, more intense immunosuppressive therapy administered in active 
patients might have also influenced the results; the results of untreated patients did, 
however, not differ from patients on immunosuppression in the parameters of T cell 
activation. Moreover, patients in remission treated with cyclophosphamide had higher 
CD3+HLA-DR+ numbers than patients on maintenance immunosuppressive therapy 
(azathioprine or mycophenolate-mofetil). In addition, based on our preliminary results, 
rituximab also leads to an increase in the numbers of CD3+HLA-DR+ cells in AAV 
patients. Thus, T cell activation in AAV seems to persist despite complete peripheral B 
cell depletion. Nonetheless, the stimulus that triggers persistent T cell activation in 
remission of AAV remains to be identified [98]. It is also questionable whether this 
finding is a cause, a bystander phenomenon or rather a consequence of the 
inflammatory process in AAV. In agreement with findings of others [94], no 
relationship between markers of T cell activation and subsequent relapse was revealed 
in this study, but an association with renewed or persistent ANCA positivity had been 
described earlier [94].  
 A detailed analysis of results obtained from active patients might help to shed 
more light on the immune processes participating in AAV. These results closely relate 
to the topic of Th1/Th2 polarization in AAV that has been studied thoroughly [reviewed 
in 116, 117] both in granulomatous lesions of the upper respiratory tract [112, 113, 118] 
and in renal biopsies [113, 119], as well as in peripheral blood [94, 97,  112, 114, 119, 
121, 161, 162], and described in detail in Chapter 2. In brief, most authors agree that 
there seems to be an aberrant Th1 type response that might play role during initiation of 
WG in patients with localized WG. On the contrary, there seems to be a significant 
appearance of Th2 cells in patients with generalized vasculitis.  
 In this study, we were not able to detect outright Th1 or Th2 polarization in 
patients with generalized AAV. Levels of both Th1- (CCR5, IL-12, IFN ) and Th2-
associated markers (CD30, CRTH2) were increased in patients with AAV when 
compared to healthy individuals. Nevertheless, while both CD30 and CRTH2 together 
with IL-10 production prevailed in active disease and correlated with disease activity 
measured with BVAS, the Th1-associated markers were either similarly increased in 
both active disease and remission (CCR5, IL-12) or significantly higher in remission 
than in active disease (CXCR3, IFN ). Thus, we speculate that Th2 type of immune 
response may play an important role in the pathogenesis of active generalized vasculitis, 
whereas Th1 type of immune response seems to predominate later in the pathogenic 
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process and in remission.  
 Soluble CD30 (sCD30) has been previously shown to correlate with disease 
activity in AAV [94, 95] but the authors did not agree on whether its levels remained 
increased in remission compared to healthy controls [94, 95]. In this study, we 
demonstrate that also the total expression of CD30 on lymphocytes as well as CD30 
expression on CD4+ lymphocytes (data not shown) correlate well with disease activity 
measured with BVAS. In agreement with Wang et al. [95] and unlike Sanders et al. [94] 
we were not able to detect significantly increased CD30 expression in remission of 
AAV. On the other hand, the significant correlation with ANCA levels described by 
Wang et al. [95] was not proven in this study. CRTH2 (chemoattractant receptor-
homologous molecule expressed on Th2
 
lymphocytes) expression is a less frequently 
used marker of Th2 type of immune response.  In this study, the expression of CRTH2 
on CD4+ T cells correlated with disease activity, and also with the CD30 expression. 
Neither CRTH2 expression in remission differed from healthy individuals, suggesting 
that Th2 cell numbers in peripheral blood tend to normalize in remission of AAV.   
 In agreement with previous reports [115], the increased expression of Th1-
associated chemokine receptor CCR5 on CD4+ T cells persisted in patients in remission 
in this study. The increased expression of CCR5 in AAV has been ascribed to the 
expanded population of effector memory T cells (TEMs) [115]. Most of TEMs in WG lack 
CD28 expression, and display upregulated CCR5, HLA-DR, CD18 ( 2 
integrin/adhesion molecule), CD152 (CTLA-4), and CD57 expression (differentiation 
marker) [132]. The majority of authors agree that CD28– TEMs secrete Th1 cytokines 
[132]. Even though not all of these markers were measured in this study, we presume 
that our findings in patients in remission (i.e. low numbers of CD4+CD45RA+ cells, 
increased numbers of HLA-DR+ cells, increased expression of CCR5, and increased 
IFN  production) conform to the presence of expanded population of TEMs in AAV. 
Increased numbers of TEMs in remission of WG when compared to active disease have 
been reported before by Abdulahad et al. [135] and explained by the migration of TEMs 
to the sites of inflammation during active disease. 
 Regarding the intracellular cytokine production, one of the prominent findings 
in our study was the increased IL-12 production in patients with active generalized 
vasculitis (both PR3-ANCA- and MPO-ANCA-associated) that persisted even in 
remission, even though a positive correlation with ANCA levels was observed. This is 
in agreement with previous studies [97, 121] and might imply a skewed regulation 
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towards Th1 cell differentiation as IL-12 is a major inducer of IFN  and as such is 
necessary for differentiation and proliferation of Th1 cells. However, in our patients, no 
correlation between IL-12 and IFN  production was observed. As mentioned before, the 
IFN  production in our active patients did not differ from controls despite increased IL-
12 production. On the contrary, in remission, IL-12 production remained higher than in 
healthy individuals but tended to decrease compared to active patients, whereas 
a significant increase in IFN  production was noted.  
 It has been proven that cytokine-primed neutrophils and monocytes (e.g. after 
stimulation with an infectious agent) are capable of translocating small amounts of 
ANCA antigens to the cell surface where they become accessible for interaction with 
ANCA, which subsequently leads to neutrophil activation [31]. Given that the IL-23-IL-
17 immune axis is probably closely associated with the rapid influx of neutrophils 
during acute infections and is thought to ―buy time‖ for the induction of Th1 response 
[124], it is conceivable that dysregulated Th17 response found in AAV [125] 
participates in the early stages of disease pathogenesis. We speculate that activated 
neutrophils not only contribute to tissue damage and attract mononuclear cells to the 
sites of inflammation, but might also be a potential source of IL-12 [168], thus 
promoting a Th1 cytokine response in the infiltrating mononuclear cells.  This process 
seems to occur especially in the initial phases of the disease. The IL-12 production in 
monocytes in our study was particularly high in newly diagnosed patients whereas in 
patients with relapse the levels were relatively low. We presume that after a long-term 
cultivation increased IFN  production in active patients might also be observed.  
 Theoretically, IL-12-induced IFN  production might be to some extent inhibited 
by the counterbalancing IL-10 in active patients. IL-10 has pleiotropic effects in 
immunoregulation and inflammation. It is an important cytokine with anti-inflammatory 
and immunosuppressive potential, suppressing especially the Th1 immune response. In 
our active patients, the IL-10 production was significantly higher than in patients in 
remission, similarly to findings of others [94] even though in our study the production 
did not significantly differ from healthy individuals. 
 Importantly, IL-10 was the only marker in this study related to the long-term 
prognosis of patients in the prospective follow-up. As mentioned earlier, many of the 
patients with AAV who successfully achieve remission undergo a relapse. Identifying 
patients at risk for relapse is one of the lasting challenges in the field of vasculitides. 
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We demonstrate that low IL-10 production at anytime in remission of the disease is 
associated with a higher probability of subsequent relapse, which in our study occurred 
in the range of 2 to 38 months after the cytokine measurement. Similar findings were 
reported in previous studies. However, in the study by Ohlsson et al. [161] low levels of 
IL-10 were observed 3 months before relapse and in the study by Sanders et al. [94] low 
levels of IL-10 were found 3 months after diagnosis and relapse was observed within 
following 60 months. We prospected for a possible correlation between the time to 
relapse and IL-10 production in our patients. Nevertheless, no such correlation was 
proven.  
 In accordance with the above mentioned significance of activation (e.g. 
infectious) stimuli in the disease pathogenesis, it seems that patients with low IL-10 are 
particularly prone to relapse after an intercurrent infection due to the lack of the anti-
inflammatory potential of IL-10. Based on the available data, IL-10 might serve as a 
marker of imminent relapse in patients with AAV, including those who seem to be in 
stable remission. This could have important therapeutic consequences, yet longitudinal 
studies monitoring intra-individual variability of IL-10 production are needed.  
 Of note, an increase in IL-10 production following rituximab (RTX) 
administration seemed to be associated with favourable treatment outcome in a small 
group of RTX-treated patients in this study. Relatively low levels of IL-10 before RTX 
administration in patients with refractory active WG correspond to our finding that 
patients with relapse had significantly lower IL-10 production than newly active 
patients. The increase in IL-10 production after RTX in patients with successful 
treatment course further highlights the importance of the anti-inflammatory and 
regulatory potential of IL-10 in AAV.  
 Talking about cellular immunity in AAV, we have to bear in mind that most 
researchers exclusively attended to patients with WG, or PR3-ANCA-associated 
disease, respectively, in their studies. Patients with MPA, or MPO-ANCA-associated 
disease, were included in few studies only [97, 98, 161, 162, 164], and detailed data are 
missing. Given the known difference in the amount of evidence for the pathogenic 
potential of PR3-ANCA and MPO-ANCA in in vivo models, with the unique presence 
of granulomatous inflammation in WG, one would also expect a considerable difference 
in cellular immunity parameters. Surprisingly, hardly any significant difference was 
found between patients with PR3-ANCA and MPO-ANCA-associated disease in this 
study, as well as in other studies [161, 164].  
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 Schönermarck et al. [162] reported on the difference in sCD30 and sCD26 
levels between generalized WG and MPA. Increased sCD30 levels and decreased 
sCD26 levels, suggesting a shift towards Th2 type of immune response, were found in 
patients with active generalized WG but not in patients with MPA. In contrast to these 
observations, the increase in CD30 expression was observed in both PR3-ANCA- and 
MPO-ANCA-associated disease in our study. It was even slightly—not significantly—
more prominent in active MPO-ANCA-associated disease than in active PR3-ANCA-
associated disease, in which CRTH2 expression predominated.  
 Furthermore, we noted lower numbers of NK cells in active PR3-ANCA-
associated disease than in active MPO-ANCA-associated disease; the biological 
significance of this is, however, uncertain. In theory, the decrease of NK cells in 
peripheral blood in WG might reflect their local role in the first wave of immune 
response to a (yet unknown) stimulus triggering granuloma formation.  
 Collectively, the examination of cellular immunity parameters in peripheral 
blood does not provide enough clues to distinguish PR3-ANCA-associated disease from 
MPO-ANCA-associated disease. It is indisputable that granulomas are not found in all 
patients with PR3-ANCA-associated disease nor do patients with PR3-ANCA 
uniformly respond to immunosuppressive therapy or follow the same course of the 
disease. Further studies might help to discern more homogenous groups within patients 
with AAV, and thus contribute to the development of ―patient-tailored‖ therapeutic 
strategies. 
 Last but not least, we investigated the possible influence of impaired renal 
function on the results of this study. Nevertheless, no correlation between glomerular 
filtration rate and measured parameters was found. Moreover, we separately analysed 
patients with serum creatinine levels below and above 300 mol/L. However, even in 
this case no significant difference was observed (data not shown).  
 Although a decrease in renal function is present in many patients with 
generalized vasculitis, most authors did not deal with direct comparison of patients with 
AAV and patients with chronic kidney disease. Ohlsson et al. [161] measured cystatin C 
as a marker of glomerular filtration and concluded that IL-6 but not IL-8 or IL-10 
seemed to be affected by decreased renal function. To elucidate this topic, we decided 
to examine a control group of patients with chronic kidney disease (CKD) caused by 
―non-immunological‖ conditions. Compatibly with findings of others [169], patients 
with CKD displayed signs of immune system activation and depletion of naïve T 
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lymphocytes (increased HLA-DR, CCR5 and CXCR3 expression, decreased numbers 
of CD4+CD45RA+, higher IFN  and TNF  production when compared to healthy 
individuals). Selected parameters are compared between patients with CKD and patients 
with AAV in Fig. 5.3-5.5.  
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Fig. 5.3: Comparison of basic subpopulations in patients with chronic kidney disease (CKD) 
and patients with AAV. Data presented as mean, error bars represent standard deviation. 
*p<0.05, ** p<0.01, *** p<0.001 
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Fig. 5.4: Comparison of the expression of selected surface molecules in patients with chronic 
kidney disease (CKD) and patients with AAV. Data presented as mean, error bars represent 
standard deviation. * p<0.05, ** p<0.01, *** p<0.001 
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Fig. 5.5: Comparison of intracellular cytokine production in patients with chronic kidney 
disease (CKD) and patients with AAV. Data presented as mean, error bars represent standard 
deviation. * p<0.05, ** p<0.01, *** p<0.001 
 
 It is obvious that some markers of immune system activation (HLA-DR and 
CCR5 expression) were equally elevated in CKD patients and AAV patients, or were 
even higher in CKD than in AAV, in particular than in active AAV (IFN  and TNF  
production). However, no shift in CD4:CD8 ratio was found in CKD. A profound 
difference between CKD patients and AAV was also observed in CD28 expression. 
Importantly, in CKD neither CD80 nor CD86 expression (increased on CD19− cells in 
remission of AAV) differed from healthy individuals. Contrary to active AAV patients, 
patients with CKD did not display increased CD30 and CRTH2 expression.  
 Taken together, activation of the immune system is present in CKD but differs 
from that in AAV in several aspects. We conclude that whilst renal insufficiency may to 
some extent contribute to persistent T cell activation in AAV, it does not seem to be the 
crucial factor for two following reasons. Firstly, we observed higher parameters of T 
cell activation in patients in remission than in active disease even though active patients 
had generally higher levels of serum creatinine than patients in remission. Secondly, the 
signs of persistent immune system activation in AAV were also described in previous 
studies in that renal involvement was missing in the majority of patients [126].  
 In conclusion, our own findings and previous published reports of others lead us 
to a current working hypothesis on the pathogenic mechanisms in AAV (Fig. 5.6) that, 
indeed, involve both humoral and cellular immune mechanisms. Even though much is 
already known, the proposed model of the disease pathogenesis provides important 
clues for future research that might help to identify possible therapeutic targets and 
improve diagnostic possibilities to predict and early detect AAV relapse. 
** 
*** 
** 
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Fig. 5.6: Current working hypothesis on the pathogenic mechanisms in AAV [freely adapted 
from 47, 132, 170].  
NEU = neutrophil, DC = dendritic cell, M/MF = monocyte/macrophage, CTL = cytotoxic T lymphocytes. 
For other abbreviations see text. 
(1) The presence of infectious agents stimulates antigen-presenting cells (e.g. DC) to produce IL-23, 
which induces differentiation and proliferation of Th17 cells. Th17 cells play role in the rapid recruitment 
of neutrophils and also stimulate monocytes/macrophages to produce pro-inflammatory cytokines.  
(2) Chemokines and pro-inflammatory cytokines attract neutrophils to the infected tissue and cause 
neutrophil priming with subsequent release and increased membrane expression of ANCA antigens, 
which become accessible for interaction with ANCA.  
(3) The inflammatory cytokines also lead to upregulation of adhesion molecules both on neutrophils and 
endothelial cells. ANCA activate neutrophils adherent to endothelial cells which results in respiratory 
burst and neutrophil degranulation. Reactive oxygen species and proteolytic enzymes cause tissue 
damage.  Released antigens also bind to endothelial cells and in the presence of ANCA form transient 
immune complexes which leads to complement activation and amplification of the immune response. 
(4, 5) Activated DCs induce both Th2 and Th1 type of immune response. Th2 cells further participate in 
B cell activation with subsequent ANCA production (4). Exaggerated Th1 type of immune response 
results in macrophage activation and plays role in the activation of cytotoxic CD8+ T lymphocytes. 
Cytokine- and/or antigen-driven expansion of CD28  T effector memory cells (TEM) occurs (5).  
(6) Both TEM and cytotoxic T lymphocytes directly contribute to the endothelial and tissue damage. 
Moreover, TEM sustain chronic granulomatous inflammation with ectopic lymphoid-like tissue formation, 
which further promotes ANCA formation.  
(7) Genetic predisposition helps to sustain the inflammatory process. Regulatory immune mechanisms 
with impaired function fail to resolve inflammation in a normal manner. 
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6. CONCLUSIONS 
 
The extent and complexity of our study have enabled us comparison with 
numerous partial studies of others. Therein, the patient cohort selection and proper 
description have been proven very important. In our experience, the studies that do not 
consider the disease activity status or the influence of immunosuppressive treatment 
may often produce distorted results.  
 
Main results of our study may be summarized into several following points: 
 Patients with AAV had decreased total number of lymphocytes and 
CD4+ cells in peripheral blood. These findings were observed even in 
untreated patients, and cannot be therefore explained by 
immunosuppressive therapy only. We suppose that decreased numbers of 
the cells in peripheral blood may reflect their increased numbers found in 
the inflammatory lesions.  
 An expansion of CD28 CD8+ subpopulation that correlated with low 
CD4:CD8 ratio and negatively correlated with ANCA levels was noted 
in remission. Further studies are needed to unambiguously elucidate the 
significance of this cell subpopulation in AAV. 
 Increased expression of CD80 and CD86 on CD19  cells found in this 
study may be ascribed to their increased expression on T cells and likely 
contributes to the persistent T cell activation in AAV. 
 The presence of T cell activation in remission of AAV was supported by 
the decrease in CD4+CD45RA+ and the increase in CD3+HLA-DR+ 
cells. These results indicate the importance of ongoing 
immunosuppressive treatment in remission.  
 We did not acquire enough evidence to detect outright Th1/Th2 
polarization in generalized AAV. However, CRTH2 expression on CD4+ 
cells correlated with disease activity but CCR5 expression on CD4+ cells 
persisted in remission. Increased IL-12 production also persisted in 
remission but did not correlate with IFN  production.  
 Low IL-10 production in remission was associated with increased risk of 
relapse.  
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 Mechanisms of immune system activation clearly differ between non-
AAV renal insufficiency and AAV.   
 
Taken together, the results reveal intriguing possibilities of further research on 
the cellular immunity in AAV. Nevertheless, they particularly demonstrate the 
persistent immune system activation in remission of AAV and warn against early 
withdrawal of immunosuppressive therapy in remission. This prompts us to future 
studies focused on the possible benefit from the long-term follow-up of cellular 
immunity parameters for guiding the maintenance immunosuppressive therapy.  
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